

---

## Medical Policy



Nonprofit corporations and independent licensees  
of the Blue Cross and Blue Shield Association

**Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.**

---

**\*Current Policy Effective Date: 7/1/24**  
(See policy history boxes for previous effective dates)

### **Title: Low-Level Laser Therapy And High-Power Laser Therapy**

---

#### **Description/Background**

**Low Level Laser therapy (LLLT) and High-Power Laser therapy (HPLT)** is also known as photo biomodulation (PBM). PBM therapy is a noninvasive and painless method of treatment in contemporary physiotherapy which produces both local and systemic effects on patients. Although the exact mechanism of action is not known PBM is purported to stimulate pain receptor cells in peripheral tissues and the immune system. This process causes vasodilatation, analgesic effects, and neurological regeneration or repair of the damaged tissues and nerves. LLLT is being evaluated to treat multiple conditions including oral mucositis, various musculoskeletal/neurologic disorders, lymphedema and wounds. HPLT is being evaluated as an intervention to reduce pain in the management of various musculoskeletal conditions.<sup>1</sup>

#### **Oral Mucositis**

Oral mucositis describes inflammation of the oral mucosa and typically manifests as erythema or ulcerations that appear 7 to 10 days after initiation of high-dose cancer therapy. Oral mucositis can cause significant pain and increased risk of systemic infection, dependency on total parenteral nutrition, and use of narcotic analgesics.

#### **Treatment**

Treatment planning may also need to be modified due to dose-limiting toxicity. There are a number of interventions for oral mucositis that may partially control symptoms, but none is considered a criterion standard treatment. When uncomplicated by infection, oral mucositis is self-limited and usually heals within 2 to 4 weeks after cessation of cytotoxic chemotherapy. Low-level laser therapy (LLLT) has been used in cancer therapy-induced oral mucositis in individuals treated with radiotherapy and/or chemotherapy and hematopoietic cell transplantation.

## **Musculoskeletal and Neurologic Disorders**

Musculoskeletal disorder describes a variety of conditions leading to chronic pain and decreased quality of life. Carpal tunnel syndrome (CTS) is the most common entrapment neuropathy and the most commonly performed surgery of the hand. The syndrome is related to the bony anatomy of the wrist. The carpal tunnel is bound dorsally and laterally by the carpal bones and ventrally by the transverse carpal ligament. Through this contained space run the 9 flexor tendons and the median nerve. Therefore, any space-occupying lesion can compress the median nerve and produce the typical symptoms of CTS: pain, numbness, and tingling in the distribution of the median nerve. Symptoms of more severe cases include hypesthesia, clumsiness, loss of dexterity, and weakness of pinch. In the most severe cases, individuals experience marked sensory loss and significant functional impairment with thenar atrophy.

### **Treatment**

Several modalities of treatment are used in the management of musculoskeletal pain including medications, immobilization, and physical therapy. The use of LLLT has been investigated for use in musculoskeletal pain conditions. In the case of CTS, mild-to-moderate cases are usually first treated conservatively with splinting and cessation of aggravating activities. Other conservative therapies include oral steroids, diuretics, nonsteroidal anti-inflammatory drugs, and steroid injections into the carpal tunnel itself. Individuals who do not respond to conservative therapy or who present with severe CTS with thenar atrophy may be considered candidates for surgical release of the carpal ligament, using either an open or endoscopic approach. Low level laser therapy is also used to treat CTS.

## **Wound Care and Lymphedema**

Chronic wounds are wounds that do not improve after 4 weeks or heal within 8 weeks. These include diabetic foot ulcers, venous-related ulcerations, non-healing surgical wounds, and pressure ulcers. They are often found on the feet, ankles, heels, and calves, and on the hips, thighs, and buttocks of those who cannot walk.

Lymphedema is described as swelling in at least 1 leg and/or arm. It is commonly caused by the removal of a lymph node. The resulting blockage of the lymphatic system prevents lymph fluid from draining well, leading to fluid build-up and swelling. Other symptoms can include heaviness or tightness in the affected limb, restricted range of motion, aching or discomfort, recurring infections, and dermal fibrosis. Risk factors for developing lymphedema after cancer from cancer treatment or from other secondary causes can include older age, obesity, and rheumatoid or psoriatic arthritis.

### **Treatment**

Chronic wound management involves ensuring adequate blood flow to the area, preventing the wound from drying, controlling infections, debriding scarred and necrotic tissue, and managing pain. The standard of care for diabetic foot ulcers includes debridement, dressings, offloading of pressure, infection management, and glycemic control. Lymphedema is typically managed with pneumatic compression, exercise, or complete decompression therapy. Use of LLLT has been investigated for the management of both chronic wounds and lymphedema.

## **Low-Level Laser Therapy**

Low level laser therapy is the use of red-beam or near-infrared lasers with a wavelength between 600 and 1,000 nm and power between 5 and 500MW. By comparison, lasers used in

surgery typically use 300 W. When applied to the skin, LLLT produces no sensation and does not burn the skin. Because of the low absorption by human skin, it is hypothesized that the laser light can penetrate deeply into the tissues where it has a photobiostimulative effect. The exact mechanism of its effect on tissue healing is unknown; hypotheses have included improved cellular repair and stimulation of the immune, lymphatic, and vascular systems.

Low level laser therapy is being evaluated to treat a wide variety of conditions, including soft tissue injuries, myofascial pain, tendinopathies, nerve injuries, joint pain, and lymphedema.

### High-Power Laser Therapy

High-power lasers (class IV therapeutic lasers; not to be confused with class IV surgical lasers) have power output of up to 7,500 mW; and supposedly offer more power, deeper penetration (can penetrate up to 10 cm<sup>2</sup> instead of 0.5 to 2.0 cm<sup>2</sup> for class III lasers) and a larger surface treatment area (cover up to 77 cm<sup>2</sup> instead of 0.3 to 5.0 cm<sup>2</sup> for class III lasers). Despite little scientific support, high-power lasers have been employed for various indications including musculoskeletal disorders (e.g., carpal tunnel syndrome and lateral epicondylitis), pain relief, and wound healing. Plaghki and Mouraux<sup>2</sup> (2005) noted that laser heat stimulators selectively activate Adelta and C-nociceptors in the superficial layers of the skin. Their high-power output produces steep heating ramps, which improve synchronization of afferent volleys and thus allow the recording of time-locked events (e.g., laser-evoked brain potentials). Study of the electrical brain activity evoked by Adelta- and C-nociceptor afferent volleys revealed the existence of an extensive, sequentially activated, cortical network. These electro-physiological responses are modulated by stimulus-driven and, even more extensively, top-down processes. The specificity and validity of these components for pain research are currently under intense scrutiny.

High power laser therapy devices, also referred to as high dose laser therapy (HDLT), (class IV therapeutic lasers) are purported to stimulate accelerated healing energy from superficial to deep levels (six to nine inches) over a larger surface treatment area. Its proposed use includes conditions such as arthritis, carpal tunnel syndrome, epicondylitis, sprains/strains, trigger points and various other musculoskeletal disorders as well as wound healing. These devices are not to be confused with class IV surgical lasers. Examples of high-power laser therapy devices that have received US Food and Drug Administration (FDA) approval are the AVI HP-7.5, AVI HPLL-12 and Diowave Laser System.

---

## Regulatory Status

**Table 1. Selected Low-Level Laser Therapy Devices Cleared by the U.S. Food and Drug Administration**

Device	Manufacturer	Date Cleared	510(k) No.	Indication
FX-635	Erchonia Corporation	6/01/2019	K190572	For adjunctive use in whole body musculoskeletal pain therapy
Super Pulsed Laser Technology	Multi Radiance Medical	01/13/2018	K171354	Providing temporary relief of minor chronic neck and shoulder pain of musculoskeletal origin

Lightstream Low-Level Laser	Solica Corporation	04/03/2009	K081166	For adjunctive use in the temporary relief of pain associated with knee disorders with standard chiropractic practice
GRT Lite, Model 8-A	Grt Solutions Inc.	02/03/2006	K050668	Use in providing temporary relief of minor chronic neck and shoulder pain of musculoskeletal origin
Microlight ML830 Laser System	Microlight Corporation of America	02/06/2002	K010175	Use in pain therapy or related indication

A number of low-level lasers have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process for the treatment of pain. Data submitted for the MicroLight ML830® Laser consisted of the application of the laser over the carpal tunnel 3 times a week for 5 weeks. The labeling states that the "MicroLight ML830 Laser is indicated for adjunctive use in the temporary relief of hand and wrist pain associated with Carpal Tunnel Syndrome." In 2006, GRT Lite™ was cleared for marketing, listing the TUCO Erchonia PL3000, the Excalibur System, the MicroLight 830® Laser, and the Acculaser Pro as predicate devices. Indications of the GRT Lite™ for CTS are similar to the predicate devices: "adjunctive use in providing temporary relief of minor chronic pain." In 2009, the LightStream™ LLL device was cleared for marketing by the FDA through the 510(k) process for adjunctive use in the temporary relief of pain associated with knee disorders treated in standard chiropractic practice. A number of clinical trials of LLLT are underway in the U. S., including studies of wound healing. Since 2009, many more similar LLT devices have received 510(k) clearance from the FDA.

### High-Power Laser Therapy Devices

High power therapeutic laser systems granted FDA 510(k) approval as "Infrared lamp", for therapeutic healing and to provide topical heating for the purpose of elevating tissue temperature for temporary relief of minor muscle and joint pain, muscle spasm, pain and stiffness associated with minor arthritis, promoting relaxing of muscle tissue, and to temporarily increase local blood circulation. These devices include not limited to:

- Diowave Lasers (formerly Avicenna Laser Technology Inc.) Riviera Beach, FL):  
Diowave Laser System, AVI HP-7.5, AVI HPLL-12
- Zimmer MedizinSystems: OptonPro

Device	Manufacturer	FDA Approved Date
AVI HP-7.5	(formerly Avicenna Laser Technology Inc.)	
AVI HPLL-12	K091285	July 2009
Diowave Laser System: The Diowave Laser System is intended to emit energy in the infrared spectrum to provide topical heating for the purpose of elevating tissue temperature for	Technological Medical Advancements, Incorporated K121363	November 2012

temporary relief of minor muscle and joint pain, muscle spasm, pain and stiffness associated with minor arthritis, promoting relaxing of muscle tissue, and to temporarily increase local blood circulation.		
OptonPro: Offers a wide range of therapy: highly effective pain therapy with local efficacy directly at the site of pain with systematic pain control.	Zimmer Medizin Systeme K141564	September 2014

---

## Medical Policy Statement

The safety and effectiveness of low-level laser therapy have been established. It may be considered a useful therapeutic option in select situations.

High-power laser therapy (nonsurgical laser) is considered investigational because evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

---

## Inclusionary and Exclusionary Guidelines

### Inclusions:

- LLLT when used for the prevention of oral mucositis in Individuals undergoing treatment associated with increased risk of oral mucositis, including chemotherapy and/or radiotherapy, and/or hematopoietic stem cell transplantation

### Exclusions:

- High Power Laser Therapy for all indications
- LLLT as a treatment, including as a physical therapy modality, for all other indications including but not limited to:
  - Carpal tunnel syndrome
  - Neck pain
  - Subacromial impingement
  - Adhesive capsulitis
  - Temporomandibular joint pain
  - Low back pain
  - Osteoarthritis knee pain

- Heel pain (ie, Achilles tendinopathy, plantar fasciitis)
- Rheumatoid arthritis
- Bell palsy
- Fibromyalgia
- Wound healing
- Lymphedema

---

**CPT/HCPCS Level II Codes** *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure)*

**Established codes:**

0552T

**Other codes (investigational, not medically necessary, etc.):**

S8948

97037

97039

**Note: The above code(s) may not be covered by all contracts or certificates. Please consult customer or provider inquiry resources at BCBSM or BCN to verify coverage.**

---

**Rationale**

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens, and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent 1 or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized controlled trials are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Aceituno-Gomez et al. (2019)<sup>3</sup> evaluated the effectiveness of high-intensity laser therapy on shoulder pain and function in subacromial impingement syndrome. A total of 46 participants with subacromial impingement syndrome were included in this study. A total of 21 patients in

high intensity laser therapy group and 22 patients in sham-laser group. No statistically differences were found between groups for pain and disability ( $P>0.05$ ). Authors concluded the effect of high-intensity laser therapy plus exercises is not higher than exercise alone to reduce pain and improve functionality in patients with subacromial syndrome.

Choi et al. (2017)<sup>4</sup> examined the effects of High Intensity Laser Therapy on pain and function of patients with chronic back pain. This study evenly divided a total of 20 patients with chronic back pain into a conservative physical therapy group that received conservative physical therapy, and a high intensity laser therapy group that received High Intensity Laser Therapy after conservative physical therapy. All patients received the therapy three times a week for four weeks. For the high intensity laser therapy group, treatment was applied to the L1-L5 and S1 regions for 10 minutes by using a high intensity laser device while vertically maintaining the separation distance from handpiece to skin at approximately 1 cm. A visual analog scale was used to measure the pain and Oswestry Disability Index was used for functional evaluation. In a within-group comparison of the conservative physical therapy and high intensity laser therapy groups, both the visual analog scale and Oswestry Disability Index significantly decreased. In a between-group comparison after treatment, the high-power laser therapy group showed a significantly lower visual analog scale and Oswestry Disability Index than the conservative physical therapy group. Authors concluded that High Intensity Laser Therapy can be an effective nonsurgical intervention method for reducing pain and helping the performance of daily routines of patients who have chronic back pain. However, this study has several limitations. First, the number of patients was small. Secondly, the daily routine of the patients were not controlled in either group. Lastly, the treatment was short and long-term effects cannot be drawn. Therefore, additional studies on the effects of high-powered laser therapy will be required in order to complement the limitations of this study.

## **PREVENTION OF ORAL MUCOSITIS**

### **Clinical Context and Therapy Purpose**

The purpose of low-level laser therapy (LLLT) in patients who have an increased risk of oral mucositis due to some cancer treatments and/or hematopoietic cell transplantation (HCT) is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does use of LLLT improve the health outcome in those who have an increased risk of oral mucositis due to some cancer treatments and/or HCT?

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals who have an increased risk of oral mucositis due to some cancer treatments and/or HCT. Oral mucositis is a common, painful complication of cancer treatments, particularly chemotherapy and radiation. It can lead to several problems including pain, nutritional problems as a result of an inability to eat, and increased risk of infection due to open sores in the mucosa.

### **Interventions**

The therapy being considered is LLLT, which can be used to treat oral mucositis. It is a non-invasive, simple, atraumatic therapeutic management corresponding to a local application of a high-density monochromatic narrow-band light source.

### **Comparators**

Oral mucositis usually heals 2 to 4 weeks after the cessation of cytotoxic chemotherapy when no infection is present. Comparators of interest include general oral care protocols and medications, including topical anesthetics, antiseptics, and analgesics.

### **Outcomes**

The general outcomes of interest are reductions in symptoms, morbid events, and treatment-related morbidity and an improvement in the quality of life (QOL). The effects of LLLT to promote healing are expected to occur from weeks to months. Outcomes can be measured using the Oral Mucositis Weekly Questionnaire-Head and Neck and the Functional Assessment of Cancer Treatment-Head and Neck Questionnaire.

### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

## **REVIEW OF EVIDENCE**

### **Systematic Reviews**

In 2014, the Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO) issued guidelines that reiterated findings from their 2012 systematic review recommending LLLT for the prevention of oral mucositis in patients receiving HCT conditioned with high-dose chemotherapy and for patients undergoing head and neck radiotherapy, without concomitant chemotherapy.<sup>1</sup> The 2014 systematic review included 24 trials on a variety of prophylactic treatments. Recommendations for the use of LLLT for prevention of oral mucositis in patients receiving HCT were based on what reviewers considered to be the well-designed, placebo-controlled, randomized trial by Schubert et al (2007),<sup>2</sup> together with "weaker evidence" from 3 observational studies that showed positive results. This phase 3 trial was double-blind and sham-controlled evaluating 70 patients.<sup>2</sup> Trial limitations included lack of statistically significant findings for the primary outcome measure and a very small percentage of patients with pain assessments. Overall, as it relates to the 3 observational studies, reviewers noted that, due to the range of laser devices and variations in individual protocols, results of each study applied exclusively to the cancer population studied and the specific wavelength and settings used.

Additional systematic reviews have been published since the MASCC/ISOO (2012) systematic review, with similar findings to support the use of LLLT.<sup>5,6,7</sup> Oberoi et al (2014) reported on a

systematic review and meta-analysis of 18 RCTs comparing LLLT with no treatment or placebo for oral mucositis in patients undergoing HCT.<sup>8</sup> Eight RCTs assessed patients undergoing HCT, 8 evaluated head and neck cancer patients receiving radiotherapy or chemoradiation, and the rest studied patients with other conditions receiving chemotherapy. Reviewers used the Cochrane risk of bias tool to evaluate the RCTs. Most were considered at low-risk of bias on most domains. For example, 68% were at low-risk of bias for blinding of patients and personnel, and 89% were at low-risk of bias on incomplete outcome data. The primary outcome measure for the review was the incidence of severe mucositis. Ten studies (N=689 patients) were included in a pooled analysis for this outcome. The overall incidence of severe mucositis (grades 3 to 4) decreased with prophylactic LLLT, with a relative risk (RR) of 0.37 (95% confidence interval [CI], 0.20 to 0.67;  $p=.001$ ). Moreover, the absolute risk reduction in the incidence of severe mucositis (-0.35) significantly favored LLLT (95% CI, -0.48 to -0.21;  $p<.001$ ). Among secondary outcomes, LLLT also significantly reduced the overall mean grade of mucositis (standardized mean difference [SMD], -1.49; 95% CI, -2.02 to -0.95), duration of severe mucositis (weighted mean difference [WMD], -5.32; 95% CI, -9.45 to -1.19), and incidence of severe pain as measured on a visual analog scale (VAS; relative risk, 0.26; 95% CI, 0.18 to 0.37). In a subgroup analysis of the primary outcome (incidence of severe mucositis), the investigators did not find a statistically significant interaction between the type of condition treated and the efficacy of LLLT.

Peng et al (2020) conducted a systematic review with meta-analysis comparing LLLT to placebo, usual care, or no therapy in patients receiving chemotherapy or radiotherapy for hematologic malignancies with or without hematopoietic stem cell transplant (HCT) or head and neck squamous cell cancer (HNSCC).<sup>9</sup> The systematic review included 30 studies including 1 with a stratified analysis. For the purposes of the meta-analysis, this was treated as an additional trial; 14 were conducted in Brazil and 10 were published between 2014 and 2018. Patients underwent HCT or chemotherapy in 19 studies; radiotherapy in 5 studies, and chemoradiotherapy in 6 studies. The application of LLLT was prophylactic in 26 studies and 6 studies reported on therapeutic LLLT use. Using the Jadad scale to assess for quality, 19 were considered high-quality (score of  $\geq 3$  out of 5 considered high quality). Ten trials were considered to be at low risk for bias. For use of prophylactic LLLT, a total of 22 studies ( $n=1190$  patients) evaluated the incidence of the primary outcome of severe oral mucositis during the treatment of hematologic disorders or head and neck cancer. Severe oral mucositis occurred significantly less in patients receiving LLLT compared to control (RR, 0.40; 95% CI, 0.25 to 0.57;  $p<.01$ ). This significant reduction in severe oral mucositis incidence with LLLT therapy was sustained in multiple subgroup analyses including by underlying condition/treatment regimen: HCT (RR, 0.46; 95% CI, 0.23 to 0.94;  $p=.03$ ), chemotherapy (RR, 0.2; 95% CI 0.05 to 0.92;  $p=.04$ ), and radiotherapy (RR, 0.36; 95% CI, 0.27 to 0.50;  $p<.01$ ). An analysis of 15 trials ( $n=900$ ) found that prophylactic LLLT numerically, but not significantly reduced, the incidence of oral mucositis of any grade (RR, 0.90; 95% CI, 0.98 to 1.00;  $p=.06$ ). A subgroup analysis of patients receiving chemotherapy showed a significant reduction in any grade of mucositis with LLLT (RR, 0.73; 95% CI, 0.55 to 0.96;  $p=.03$ ); this difference was not significant in patients receiving radiotherapy and chemoradiotherapy (RR, 1.00; 95% CI, 0.92 to 1.09; and RR, 1.00; 95% CI, 0.98 to 1.01, respectively).

### **Section Summary: Prevention of Oral Mucositis**

The literature on LLLT for the prevention of oral mucositis includes several systematic reviews, including a review by MASCC/ISOO (2012), with a resulting recommendation for LLLT for

adults receiving HCT conditioned with high-dose chemotherapy. The MASCC/ISOO recommendation for LLLT for preventing oral mucositis in patients undergoing radiotherapy for head and neck cancer was based on lower level evidence. Several systematic reviews have found benefit of LLLT, including a 2014 systematic review of LLLT for prevention of oral mucositis in patients undergoing HCT that included 18 RCTs, generally considered at low risk of bias, and found statistically significantly better outcomes with LLLT than with control conditions on primary and secondary outcomes.

## **CARPAL TUNNEL SYNDROME**

### **Clinical Context and Therapy Purpose**

The purpose of LLLT in individuals who have carpal tunnel syndrome (CTS) is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does the use of LLLT improve the net health outcome in individuals who have CTS?

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals who have CTS, a common condition that causes pain, numbness, and tingling in the hand and arm. It is due to excess pressure in the wrist and on the median nerve, often caused by inflammation. Repeated motion of the wrist can contribute to the syndrome such as any repeated movement that overextends the wrist.

Women are more likely to have CTS than men, and it is frequently diagnosed between the ages of 30 and 60 years. Certain conditions can also increase the risk of developing CTS, including diabetes mellitus, high blood pressure, and arthritis.

### ***Interventions***

The therapy being considered is LLLT. Possible mechanisms of the benefits of LLLT include anti-inflammatory effects, selective inhibition of nociceptive activation at peripheral nerves, increased adenosine triphosphate (ATP) production and cellular respiration, and improvement of blood circulation to remove algescic substances.

### ***Comparators***

The following practice is currently used to treat CTS: conservative therapy (eg, physical therapy, wrist splints) and medication for pain and inflammation. Surgery may also be performed, during which the transverse carpal ligament is cut, often under local anesthetic.

### ***Outcomes***

The general outcomes of interest are improvements in functional outcomes and QOL and a reduction in treatment-related morbidity. The effects of LLLT to promote healing are expected to occur from weeks to months. Pain can be measured on a VAS score.

### **Study Selection Criteria**

See the information under the first indication.

## REVIEW OF EVIDENCE

### Systematic reviews

A TEC Assessment (2010) evaluated LLLT for CTS and chronic neck pain.<sup>10</sup> For inclusion in the Assessment, studies had to meet the following criteria: be published in a peer-reviewed journal; be a randomized, sham-controlled trial, and, if adjunctive therapies were used, they had to have been applied to both groups; and measure outcomes at least 2 weeks beyond the end of the treatment period. Four RCTs met the inclusion criteria. Reviewers concluded that the studies had serious limitations, including small sample sizes and limited follow-up, and no study was so methodologically sound as to provide definitive results.

A 2016 Cochrane report assessed the benefits and harms of LLLT compared with placebo and compared with other non-surgical interventions in the management of CTS.<sup>11</sup> Twenty-two RCTs with 1153 participants were included. The authors concluded the quality of evidence was very low and found no data to support a clinical effect of LLLT in treating CTS.

Li et al (2016) published a meta-analysis of RCTs on LLLT for CTS.<sup>12</sup> Reviewers identified 7 RCTs. Meta-analyses evaluated outcomes for hand grip strength, pain measured by a VAS, symptom severity scores and functional status scores. Short-term follow-up was defined as less than 6 weeks after treatment and long-term follow-up as at least 12 weeks after treatment. For 6 of the 8 meta-analyses, there were not statistically significant between-group differences in outcomes. They included short-term assessment of hand grip, short-term assessment of pain (VAS), and short- and long-term assessment of symptom severity and functional status scores. Meta-analyses found stronger hand grip (3 studies) and greater improvement in VAS score (2 studies) at the long-term follow-up in the LLLT group than in the control. Most data for these 2 positive analyses were provided by a single RCT (Fusakul et al [2014]<sup>13</sup>). Reviewers concluded that additional high-quality trials with similar LLLT protocols would be needed to confirm that the intervention significantly improves health outcomes.

### Section Summary: Carpal Tunnel Syndrome

A number of RCTs and several systematic reviews have been published. The most recent systematic review (2016) identified 7 RCTs. Meta-analyses did not find a significant benefit of LLLT compared with a control condition on most of the outcome measures (6 of 8). Previously, a TEC Assessment (2010) concluded that the evidence from sham-controlled RCTs was insufficient. More recent RCTs have not found that LLLT significantly improves outcomes.

## NECK PAIN

### Clinical Context and Therapy Purpose

The purpose of LLLT in individuals who have neck pain is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

### Populations

The relevant population of interest is individuals who have neck pain. Accompanying symptoms can include muscle tightness and spasms, decreased mobility, and headache. It can be caused by muscle strain, worn joints, nerve compression, injuries, or disease.

### **Interventions**

The therapy being considered is LLLT, which uses laser irradiation to help repair tissue and relieve pain.

### **Comparators**

The following practices are currently being used to treat neck pain: conservative therapy (eg, physical therapy), medication, and surgery.

### **Outcomes**

The general outcomes of interest are improvements in functional outcomes and QOL and a reduction in symptoms and treatment-related morbidity. The effects of LLLT to promote healing are expected to occur from weeks to months. Pain can be measured on a VAS score.

### **Study Selection Criteria**

See the information under the first indication.

## **REVIEW OF EVIDENCE**

### **Systematic review**

The TEC Assessment (2010) which included 6 trials of LLLT for chronic neck pain found inconsistent results.<sup>14</sup> In the largest study (Chow et al [2006]) 90 patients were randomized to active LLLT or sham treatment.<sup>15</sup> Five weeks after the 7-week treatment period, patients in the active treatment group reported a 2.7 point improvement in VAS pain versus a 0.3 point worsening for the sham group. A calculated mean improvement of 43.8% was reported for the active LLLT group while the sham-treated group improved by 2.1%. The Assessment noted that baseline VAS pain scores were significantly higher in the active treatment group possibly biasing results in favor of LLLT. Overall, reviewers concluded that the trials were characterized by small sample sizes, limited statistical power, and limited long-term follow-up and thus the evidence was insufficient.

In a systematic review and meta-regression, Gross et al (2013) evaluated 17 trials on LLLT for neck pain.<sup>16</sup> Ten trials demonstrated high risk of bias. Two trials (N=109 subjects) were considered to be of moderate quality and found LLLT produced better outcomes than placebo for chronic neck pain treatment. Other trials showed improved outcomes with LLLT compared with placebo for acute neck pain, acute radiculopathy and cervical osteoarthritis but they were considered to be low-quality. There was conflicting evidence on chronic myofascial neck pain.

### **Section Summary: Neck Pain**

A number of RCTs and several systematic reviews have been published. A 2013 systematic review identified 17 trials. Only 2 trials considered of moderate quality found that LLLT led to better outcomes than placebo for chronic neck pain. Other trials were considered low-quality. A 2010 TEC Assessment found conflicting evidence. While some studies showed positive benefits with LLLT over placebo, others did not. Additionally, laser types, dosages and treatment schedules varied in the available evidence.

## **SUBACROMIAL IMPINGEMENT SYNDROME**

### **Clinical Context and Therapy Purpose**

The purpose of LLLT in individuals with subacromial impingement syndrome is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals who have subacromial impingement syndrome, involving tendonitis of the rotator cuff muscles as they pass through the subacromial space. It can result in pain, weakness, and loss of movement at the shoulder.

### ***Interventions***

The therapy being considered is LLLT.

### ***Comparators***

The following practice is currently being used to treat subacromial impingement syndrome: conservative therapy (eg, physical therapy, rest, cessation of painful activity), medication (such as corticosteroids and local anesthetics), and surgery. Surgery can be done arthroscopically or as open surgery.

### ***Outcomes***

The general outcomes of interest are improvements in functional outcomes and QOL and a reduction in symptoms and treatment-related morbidity. The effects of LLLT to promote healing are expected to occur from weeks to months. Pain can be measured on a VAS score and on the Shoulder Pain and Disability Index (SPADI).

### **Study Selection Criteria**

See the information under the first indication.

## **REVIEW OF EVIDENCE**

### **Randomized Controlled Trials**

Several RCTs evaluating LLLT for treatment of subacromial impingement syndrome have been published. Two sham-controlled studies, by Yeldan et al (2009)<sup>17</sup> and by Dogan et al (2010)<sup>18</sup> did not find statistically significantly better pain or function outcomes with active treatment than with sham. A third RCT, published by Abrisham et al (2011), compared exercise plus pulsed LLLT or sham laser 5 times per week for 2 weeks in 80 patients who had a subacromial syndrome (rotator cuff and biceps tendinitis).<sup>19</sup> At the end of treatment, while both groups had improved VAS scores for pain and shoulder range of motion (ROM), the improvements were significantly better for the active LLLT group than for the sham laser group for pain (VAS score, 4.4 vs. 2.9), and all measures of ROM (active and passive flexion, abduction, external rotation). The durability of this effect was not assessed.

Other RCTs did not show statistically significant benefits of LLLT versus conservative treatment. In a study designed to assess the effectiveness of LLLT in patients with subacromial impingement syndrome, Bal et al (2009) randomized 44 patients to a 12-week home exercise

program with or without LLLT.<sup>20</sup> Outcome measures of night pain, SPADI, and University of California-Los Angeles shoulder pain end-result scores were assessed at weeks 2 and 12 of the intervention. No distinct advantage was demonstrated by LLLT over exercise alone. Both groups showed significant reductions in night pain and SPADI scores at 2- and 12-week assessments, but the differences between groups were not statistically significant.

Calis et al (2011) randomized 52 patients with subacromial impingement syndrome to LLLT, ultrasound, or exercise.<sup>21</sup> Patients were treated 5 days a week for 3 weeks with hot pack plus ultrasound plus exercise, hot pack plus LLLT plus exercise, or hot pack plus exercise. All 3 groups showed improvement from baseline to posttreatment in pain at rest, ROM, and function, but between-group improvements with LLLT were not statistically significant.

Alfredo et al (2020) randomized 122 patients to LLLT plus exercise (n=44; 42 included in analysis), LLLT alone (n=42), or exercise alone (n=42) for 8 weeks.<sup>22</sup> Therapy was given 3 times a week for 8 weeks. Between-group comparison showed that patients in the LLLT plus exercise group had a significantly greater improvement in SPADI compared to other groups; however, no between-group comparison was performed exclusively for patients receiving LLLT alone and exercise alone.

Badil Güloğlu (2021) randomized 64 patients with a recent diagnosis of subacromial impingement syndrome without treatment in the preceding 4 weeks to 15 sessions of LLLT (n=34) every weekday for 3 weeks or to weekly sessions of extracorporeal shock wave treatment (ESWT; n=30) for 3 weeks.<sup>23</sup> In both groups, all range of motion measurements, visual analogue scale pain scores, and SPADI scores showed significant improvements both at the end of treatment and at the third month after treatment ( $p < .05$ ). There was no significant difference in abduction between the groups except the change at the end of treatment ( $p > .05$ ). The ESWT group showed greater improvements in terms of SPADI disability and total scores at the end of treatment compared to LLLT. The improvements in VAS pain scores and SPADI scores at the third month after treatment was significantly more evident in the ESWT group ( $p < .05$ ). Tables 2 and 3 provide RCT characteristics and results for evaluation of treatment of subacromial impingement syndrome.

**Table 2. Summary of Key RCT Characteristics**

Study	Countries	Sites	Dates	Participants	Interventions	
					Active	Comparator
Yeldan et al (2009) <sup>14</sup>	Turkey	1	NR	Patients with SAIS	LLLT (n=34)	Placebo (n=33)
Bal et al (2009) <sup>17</sup>	Turkey	1	NR	Newly-diagnosed SAIS patients	LLLT + 12-wk home exercise program (n=22)	12-wk home exercise program (n=22)
Dogan et al (2010) <sup>15</sup>	Turkey	NR	NR	Patients with SAIS	LLLT (n=30)	Placebo (n=22)
Abrisham et al (2011) <sup>16</sup>	Iran	1	NR	Patients with SAIS (rotator cuff and biceps tendinitis)	LLLT (n=40)	Placebo (n=40)

Calis et al (2011) <sup>18</sup>	Turkey	NR	NR	Patients with SAIS	LLLT + moist heat + exercise (n=15)	Comparator 1: Moist heat + ultrasound + exercise (n=21) Comparator 2: Moist heat + exercise (n=16)
Alfredo et al (2020) <sup>19</sup>	Brazil	1	2015-2016	Patients with SAIS, aged 50 to 70 years	LLLT + exercise (n=42); LLLT alone (n=36)	Exercise only (n=42)
Badil Güloğlu (2021) <sup>23</sup>	Turkey	1	2019	Patients with newly diagnosed SAIS, aged 18 to 65 years	LLLT (n=34)	ESWT (n=30)

ESWT: extracorporeal shock wave therapy; LLLT: low-level laser therapy; NR: not reported; RCT: randomized controlled trial; SAIS: subacromial impingement syndrome.

**Table 3. Summary of Key RCT Results**

Study	Pain	ROM (°)
Yeldan et al (2009) <sup>17</sup>	<b>VAS-A; VAS-R; VAS-N (Change from Baseline)</b>	NR
LLLT	-2.20 ± 1.78; -1.47 ± 2.12; -2.85 ± 1.98	
Placebo	-2.15 ± 2.11; -2.03 ± 2.45; -3.07 ± 2.81	
P-value	.94; .30; .79	
Bal et al (2009) <sup>20</sup>	<b>SPADI (Change from Baseline)</b>	NR
LLLT	-37 ± 18.58	
Exercise	-37.2 ± 21.28	
P-value	.486	
Dogan et al (2010) <sup>18</sup>	<b>VAS (Baseline; Posttreatment)</b>	NR
LLLT	7.16 ± 1.64; 3.76 ± 1.45	
Placebo	7.59 ± 1.76; 4.63 ± 2.10	
P-value	.343; .216	
Abrisham et al (2011) <sup>19</sup>	<b>VAS (Posttreatment)</b>	<b>Active Flexion, mean</b>
LLLT	4.4 ± 1.2	43.1 ± 2.5
Placebo	2.9 ± 1.1	25.3 ± 2.4
P-value	.000	.000
Calis et al (2011) <sup>21</sup>	<b>VAS at Rest (Baseline; Posttreatment)</b>	<b>Flexion (Baseline; Posttreatment)</b>
LLLT	4.00 ± 3.45; 2.56 ± 2.28	163.80 ± 10.05; 174.46 ± 6.94
Ultrasound	3.56 ± 2.49; 2.21 ± 2.09	168.33 ± 1.34; 177.04 ± 3.74
Control	4.67 ± 2.47; 3.96 ± 2.71	163.06 ± 8.57; 172.18 ± 6.93
P-value	.49; .10	.21; .05
Alfredo et al (2020) <sup>22</sup>	<b>SPADI (Posttreatment value [median quartile])</b>	<b>Flexion (Baseline; Posttreatment)</b>
LLLT + exercise	0 (0 to 10)	132.9 ± 27.1; 161.5 ± 10.9
LLLT	16 (10.0 to 27.5)	124.9 ± 35.0; 153.5 ± 17.9
Exercise	41 (8.0 to 86.0)	118.4 ± 28.1; 137.1 ± 24.1
P-value	<.001	<.001
Badil Güloğlu (2021) <sup>23</sup>	<b>SPADI (End of treatment; Third month after treatment)</b>	<b>Change in Abduction (Before Treatment to End of Treatment Difference)</b>
LLLT	48 (range, 12 to 92); 52 (range, 12 to 80)	-10 to 100; median, 30
ESWT	35 (range, 0 to 76); 32 (range, 0 to 68)	0 to 50; median, 20

P-value	.003;.002	.018
---------	-----------	------

-A: activity; ESWT: extracorporeal shock wave therapy; LLLT: low level laser therapy; -N: night; -R: rest; ROM: range of motion; SPADI: shoulder pain and disability index; VAS: visual analog scale.

Tables 4 and 5 display notable limitations identified in each study.

**Table 4. Subacromial Impingement Syndrome RCT Study Relevance Limitations**

Study	Population <sup>a</sup>	Intervention <sup>b</sup>	Comparator <sup>c</sup>	Outcomes <sup>d</sup>	Follow-Up <sup>e</sup>
Yeldan et al (2009) <sup>17</sup>	4. 78.3% of included in the analysis were female				1,2. Follow-up duration only 3 weeks
Bal et al (2009) <sup>20</sup>	4. 70% of patients included in the analysis were female				
Dogan et al (2010) <sup>18</sup>					1,2. Follow-up duration not specified
Abrisham et al (2011) <sup>19</sup>					1,2. Follow-up duration only 3 weeks
Calis et al (2011) <sup>21</sup>					
Alfredo et al (2020) <sup>22</sup>	3. Detailed baseline characteristics (eg, gender) not presented				
Badil Güloğlu (2021) <sup>23</sup>	4. 70.6% of patients in the LLLT group were female		2., 3. ESWT efficacy not completely established.		

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive limitations assessment.

<sup>a</sup> Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

<sup>b</sup> Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest.

<sup>c</sup> Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.

<sup>d</sup> Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.

<sup>e</sup> Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

**Table 5. Subacromial Impingement Syndrome RCT Study Design and Conduct Limitations**

Study	Allocation <sup>a</sup>	Blinding <sup>b</sup>	Selective Reporting <sup>c</sup>	Follow-Up <sup>d</sup>	Power <sup>e</sup>	Statistical <sup>f</sup>
Yeldan et al (2009) <sup>17</sup>	2. Allocation not concealed	2. Blinding unclear				
Bal et al (2009) <sup>20</sup>	3. Allocation concealment unclear	1,2,3. Blinding unclear				
Dogan et al (2010) <sup>18</sup>	3. Allocation concealment unclear					
Abrisham et al (2011) <sup>19</sup>	3. Allocation concealment unclear	1,2,3. Blinding not described				

Calis et al (2011) <sup>21</sup>	3. Allocation concealment unclear	1,2,3. Not blinded				
Alfredo et al (2020) <sup>22</sup>		1,2,3 Not blinded		6. Per protocol analysis performed; however, only 2 patients were excluded from this analysis		4. No comparative analysis performed to compare LLLT only group with exercise only group
Badil Güloğlu (2021) <sup>23</sup>		1,2,3. Not blinded		6. Per protocol analysis performed (7 patients excluded from analysis)		

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive limitations assessment.

<sup>a</sup> Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear;

4. Inadequate control for selection bias.

<sup>b</sup> Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

<sup>c</sup> Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

<sup>d</sup> Follow-Up key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

<sup>e</sup> Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

<sup>f</sup> Statistical key: 1. Intervention is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Intervention is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

## Section Summary: Subacromial Impingement Syndrome

The literature on LLLT for subacromial impingement syndrome consists of several RCTs. Most trials failed to show a significant benefit of LLLT compared with sham treatments or alternative interventions (eg, exercise).

## ADHESIVE CAPSULITIS

### Clinical Context and Therapy Purpose

The purpose of LLLT in individuals who have adhesive capsulitis is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does the use of LLLT improve the net health outcome in individuals who have adhesive capsulitis?

The following PICO was used to select literature to inform this review.

### Populations

The relevant population of interest is individuals who have adhesive capsulitis, also known as frozen shoulder. In this condition, the connective tissue surrounding the glenohumeral joint becomes inflamed, stiff, and painful.

Risk factors for adhesive capsulitis include tonic seizures, diabetes mellitus, stroke, and lung, heart, and thyroid diseases. It occurs most frequently in women aged 40 to 65 years.

### **Interventions**

The therapy being considered is LLLT.

### **Comparators**

The following practices are currently being used to treat adhesive capsulitis: conservative therapy (eg, physical therapy), medication, and surgery.

### **Outcomes**

The general outcomes of interest are improvements in functional outcomes and QOL and a reduction in symptoms and treatment-related morbidity. The effects of LLLT to promote healing are expected to occur from weeks to months. Outcomes can be measured using the SPADI and the Croft Shoulder Disability Questionnaire.

### **Study Selection Criteria**

See the information under the first indication.

## **REVIEW OF EVIDENCE**

### **Systematic Review**

A Cochrane review by Page et al (2014) evaluated LLLT and other electrotherapy modalities for adhesive capsulitis (ie, frozen shoulder).<sup>24</sup> Reviewers found limited evidence on which to conclude whether electrotherapy modalities are effective for frozen shoulder. Only 1 RCT (N=40) compared LLLT with placebo. That trial administered LLLT for 6 days. On day 6, patients receiving LLLT showed some improvement on a global assessment of treatment success compared with patients receiving placebo. However, this trial was considered of low-quality, and its small sample size and short follow-up limited interpretation of results. Another RCT on LLLT discussed in the 2014 Cochrane review was assessed as moderate quality. In that RCT, Stergioulas et al (2008) randomized 63 patients with frozen shoulder to an 8-week program of LLLT (n=31) or placebo (n=32).<sup>25</sup> Both groups also participated in exercise therapy. Compared with the sham group, the active laser group had a significant decrease in overall, night, and activity pain scores after 4 and 8 weeks of treatment; and at the end of 8 more weeks of follow-up. At the same assessment intervals, significant decreases in Shoulder Pain and Disability Index and Croft Shoulder Disability Questionnaire scores were observed, while significant decreases in Disability of Arm, Shoulder, and Hand Questionnaire scores were observed at 8 weeks of treatment and at 16 weeks post-randomization; significant decreases in Health Assessment Questionnaire scores were observed at 4 weeks and 8 weeks of treatment.

### **Section Summary: Adhesive Capsulitis**

A Cochrane review on treatments for adhesive capsulitis identified 2 RCTs on LLLT for adhesive capsulitis and, due to the small number of trials and study limitations, concluded that the evidence was insufficient to conclude whether LLLT is effective for adhesive capsulitis.

## **TEMPOROMANDIBULAR (TMJ) PAIN**

### **Clinical Context and Therapy Purpose**

The purpose of LLLT in individuals who have temporomandibular joint (TMJ) pain is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does the use of LLLT improve the net health outcome in individuals who have TMJ pain?

The following PICO was used to select literature to inform this review.

### **Populations**

The relevant population of interest is individuals who have TMJ pain.

### **Interventions**

The therapy being considered is LLLT.

### **Comparators**

The following practices are currently being used to treat TMJ pain: conservative therapy (eg, physical therapy), medication, and surgery.

### **Outcomes**

The general outcomes of interest are improvements in functional outcomes and QOL and a reduction in symptoms and treatment-related morbidity. The effects of LLLT to promote healing are expected to occur from weeks to months.

### **Study Selection Criteria**

See the information under the first indication.

## **REVIEW OF EVIDENCE**

### **Systematic Review**

Several meta-analyses of RCTs on LLLT for temporomandibular joint (TMJ) pain have been published. A meta-analysis by Chen et al (2015) assessed pain and functional outcomes after LLLT for TMJ pain.<sup>26</sup> Fourteen placebo-controlled randomized trials were identified. Ten trials provided data on pain, as measured by a VAS. Pooled analysis of these studies found no significant differences between active treatment and placebo for VAS scores at final follow-up (WMD= -19.39; 95% CI, -40.80 to 2.03; p=.08). However, meta-analyses did find significantly better functional outcomes (ie, maximum active mouth opening, maximum passive mouth opening) favoring LLLT. For example, the mean difference in maximum active mouth opening for active treatment versus placebo was 4.18 (95% CI, 0.73 to 7.63).

Chang et al (2014) published a meta-analysis of 7 RCTs on LLLT for TMJ pain.<sup>27</sup> Single- or double-blind RCTs included in the review compared LLLT with no treatment or placebo. The primary outcome of interest was pain measured by a VAS. Six studies (N=223) were eligible for inclusion in the meta-analysis; reduction in VAS scores after treatment was significantly greater in the LLLT group than in the control group (pooled effect size, -0.6, 0.6; 95% CI, -0.47 to -0.73).

Hanna et al (2021) recently published the largest systematic review including 44 RCTs of LLLT for TMJ pain to date.<sup>28</sup> All included trials were at low risk for reporting missing outcome data. Seventy percent of the included trials were at low risk, 28% were at high risk, and 2% had some concerns in terms of reporting outcome measurement. Of the RCTs included, 98% were

at low risk of bias for selective reporting of the results. Overall, 38% of studies reported a low risk of bias, 46% were at high risk, and 16% had some concerns. Comparators across RCTs included sham placebo, drug therapy and physiotherapy. The primary outcome of interest was change in pain intensity reduction from baseline, measured by a VAS. Thirty-three studies (n=1163) were eligible for inclusion in the meta-analysis. In a meta-analysis, pooled change in VAS score from baseline to final follow-up evaluation demonstrated a significantly greater reduction with LLLT compared to comparator groups (pooled SMD, -0.55; 95% CI, -0.82 to -0.27;  $p < .0001$ ), however, heterogeneity was high ( $I^2 = 78\%$ ).

Tables 6 through 8 provide further details of these systematic reviews.

**Table 6. Comparison of Trials/Studies Included in Systematic Reviews & Meta-Analysis**

Study	Chen et al (2015) <sup>23,</sup>	Chang et al (2014) <sup>24,</sup>	Hanna et al (2021) <sup>25,</sup>
Conti et al (1997) <sup>29,</sup>	●		
Kulekcioglu et al (2003) <sup>30,</sup>	●		
Venancio et al (2005) <sup>31,</sup>	●	●	●
Cetiner et al (2006) <sup>32,</sup>		●	●
Fikackova et al (2007) <sup>33,</sup>		●	●
Mazzetto et al (2007) <sup>34,</sup>	●	●	●
Frare et al (2008) <sup>35,</sup>			●
Da Cunha et al (2008) <sup>36,</sup>	●	●	●
Lassemi et al (2008) <sup>37,</sup>			●
Carrasco et al (2008) <sup>38,</sup>	●	●	●
Emshoff et al (2008) <sup>39,</sup>	●	●	●
Carrasco et al (2009) <sup>40,</sup>			●
Shirani et al (2009) <sup>41,</sup>	●		●
Venezian et al (2010) <sup>42,</sup>			●
Oz et al (2010) <sup>43,</sup>			●
Marini et al (2010) <sup>45,</sup>	●		●
Rohlig et al (2011) <sup>45,</sup>			●
Sattayut et al (2012) <sup>56,</sup>	●		●
de Carli et al (2012) <sup>47,</sup>			●
da Silva et al (2012) <sup>48,</sup>	●		●
Panhoca et al (2013) <sup>49,</sup>			●
Uemoto et al (2013) <sup>50,</sup>			●
Ferreira et al (2013) <sup>51,</sup>	●		
Demirkol et al (2014) <sup>52,</sup>	●		

Ahrari et al (2014) <sup>53,</sup>	●		●
Pereira et al (2014) <sup>54,</sup>			●
Maia et al (2014) <sup>55,</sup>			●
Sancakli et al (2015) <sup>56,</sup>			●
De Oliveira et al (2017) <sup>57,</sup>			●
Costa et al (2017) <sup>58,</sup>			●
Seifi et al (2017) <sup>59,</sup>			●
Shobha et al (2017) <sup>60,</sup>			●
Rezazadeh et al (2017) <sup>61,</sup>			●
Varma et al (2018) <sup>62,</sup>			●
Borges et al (2018) <sup>63,</sup>			●
Brochado et al (2018) <sup>64,</sup>			●
Rodrigues et al (2018) <sup>65,</sup>			●
Peimani et al (2018) <sup>66,</sup>			●
Nadershah et al (2019) <sup>67,</sup>			●
Magri et al (2019) <sup>68,</sup>			●
Al-Quisi et al (2019) <sup>69,</sup>			●
Herpich et al (2019) <sup>70,</sup>			●
Khairnar et al (2019) <sup>71,</sup>			●
Sobral et al (2020) <sup>72,</sup>			●
Maracci et al (2020) <sup>73,</sup>			●
Chellappa et al (2020) <sup>74,</sup>			●
Monteiro et al (2020) <sup>75,</sup>			●

**Table 7. Systematic Reviews & Meta-Analysis Characteristics**

Study	Dates	Trials	Participants	N (Range)	Design	Duration
Chen et al (2015) <sup>26</sup>	2003-2014	14	Patients suffering from TMDs	454 (NR)	RCT	NR
Chang et al (2014) <sup>26</sup>	2006-2008	7	Patients suffering from TMDs	NR (NR)	RCT	NR
Hanna et al (2021) <sup>28</sup>	2005-2021	44	Patients with TMDs	1163 (10 to >50)	RCT	4 days to 8 weeks

NR: not reported; RCT: randomized controlled trial; TMD: temporomandibular disorders.

**Table 8. Systematic Reviews & Meta-Analysis Results**

Study	Pain (VAS)	MAVO	MPVO
-------	------------	------	------

Chen et al (2015) <sup>26</sup>			
WMD	-19.39	4.18	6.73
95% CI	-40.80 to 2.03	0.73 to 7.63	1.34 to 12.13
P-value	<.001	.006	.06
Chang et al (2014) <sup>27</sup>			
ES (95% CI)	-0.60 (-0.47 to -0.73)	NR	NR
Hanna et al (2021) <sup>28</sup>			
SMD (95% CI)	-0.55 (0.83 to -0.28)	-0.40 (-0.61 to -0.20)	NR
P-value	<.0001	.0001	
I <sup>2</sup> (p)	78% (<.0001)	0% (.56)	

CI: confidence interval; MAVO: maximum active vertical opening; MPVO: maximum passive vertical opening; ES: effect size; SMD: standard mean deviation; VAS: visual analog scale; WMD: weighted mean difference.

### Randomized Controlled Trials

Several RCTs have been published since the meta-analyses, showing inconsistent results

Del Vecchio et al (2021) randomized 90 patients between the ages of 18 and 73 years old with TMJ disorders to home LLLT (808 nm, 5 J/min, 250 mW, 15 KHz for 8 minutes twice daily), sham control, or standard conventional drugs (nimesulide 100 mg daily with 5-days of cyclobenzaprine 10 mg daily) for 1 week.<sup>76</sup> Pain was measured using a 100-mm VAS, and the examiner was blinded. At the end of treatment, the reduction in VAS was greater in the LLLT group (MD, 13.030; p=.036) and the drug group (MD, 14.409; p=.17) compared to the sham group. However, no significant difference in pain reduction was observed between the LLLT group and the drug group (MD, 1.379; p=1). This study evaluated a specific at-home LLLT protocol and can not be generalized to other LLLT regimens.

Aisaiti et al (2021) randomized 78 patients with TMJ pain to receive LLLT (810 nm, 6 J/cm<sup>2</sup>, applied at 5 points for 30 seconds) or placebo once daily for 7 consecutive days.<sup>77</sup> Pain was measured on a 0 to 10 numerical rating scale and pressure pain thresholds. Only 50 patients, 25 per group, remained in the study to contribute data to analysis. Greater reduction in numerical rating scale pain scores were seen with LLLT than with placebo (p=.014), but no significant interaction between time and intervention was found (p=.35). For pressure pain thresholds, there was no significant difference found between interventions or interaction between time and intervention.

### Section Summary: Temporomandibular Joint Pain

A number of RCTs and several systematic reviews have evaluated LLLT for TMJ pain. Meta-analyses of these trials had mixed findings. The largest and most recent meta-analysis, using 33 randomized trials, found a statistically significant impact of LLLT on pain reduction and functional outcomes (eg, mouth opening) compared with sham laser or other therapies including drug therapy; however, heterogeneity was high among included trials. Randomized controlled trials have not compared the impact of LLLT with physical therapy on health outcomes.

## LOW BACK PAIN

### **Clinical Context and Therapy Purpose**

The purpose of LLLT in individuals who have low back pain is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does the use of LLLT improve the net health outcome in individuals who have low back pain?

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals who have low back pain. It can be the result of an injury, such as muscle strains, or disease.

### ***Interventions***

The therapy being considered is LLLT.

### ***Comparators***

The following practices are currently being used to treat low back pain: conservative therapy (eg, physical therapy), medication, and surgery. These medications can include muscle relaxants and nonsteroidal anti-inflammatory drugs.

### ***Outcomes***

The general outcomes of interest are improvements in functional outcomes and QOL and a reduction in symptoms and treatment-related morbidity. The effects of LLLT to promote healing are expected to occur from weeks to months.

### **Study Selection Criteria**

See the information under the first indication.

## REVIEW OF EVIDENCE

### **Systematic Review**

A number of RCTs and several systematic reviews of RCTs have assessed LLLT for low back pain. For example, Glazov et al (2016) published a meta-analysis of blinded sham-controlled trials evaluating LLLT for treatment of chronic low back pain.<sup>78</sup> Fifteen RCTs (N=1039) met reviewers' eligibility criteria. Reviewers found that 3 of the 15 trials were at higher risk of bias (using a modified Cochrane risk of bias tool), mainly due to lack of blinding. The primary outcomes of interest to reviewers were pain measured by a VAS or a numeric rating scale, and a global assessment measure evaluating overall improvement and/or satisfaction with the intervention. Outcomes were reported immediately posttreatment (<1 week) and at short-term (1 to 12 weeks) follow-up. Longer-term outcomes (ie, at 6 and 12 months) were secondary measures. For the pain outcomes, a meta-analysis of 10 trials found a significantly greater reduction in pain scores in the LLLT group at immediate follow-up (WMD = -0.79 cm; 95% CI, -1.22 to 0.36 cm). In a meta-analysis of 6 trials, there was no significant difference in pain reduction at short-term follow-up. However, in subgroup analyses, there was a significantly greater reduction in pain with LLLT in trials that used a higher dose (>3 J/point), but not a lower

dose, and in trials that included patients with a short duration of back pain (5 to 27 months) but not long duration (49 months to 13 years). Decisions on the cutoff to use for laser dose and duration of back pain was made post hoc and considered review findings. Findings were similar for the global assessment outcome. Meta-analyses found significantly higher global assessment scores at immediate follow-up (5 trials) but not at short-term follow-up (3 trials). Only 2 trials reported pain or global assessment at 6 months and 12 months and neither found statistically significant differences between the LLLT and sham groups.

Huang et al (2015) published a systematic review of RCTs on LLLT for treating nonspecific chronic low back pain.<sup>79</sup> Reviewers included trials comparing LLLT and placebo that reported pain and/or functional outcomes and a Physiotherapy Evidence Database (PEDro) quality score. Seven trials (N=394; 202 assigned to LLLT, 192 assigned to placebo) were included. Six of the 7 trials were considered high quality (ie, a PEDro score  $\geq 7$ ; maximum score, 11 points). Primary outcomes of interest were post-treatment pain measured by VAS and disability measured by the Oswestry Disability Index (ODI) score. Change in pain and ROM scores were secondary outcomes. In pooled analyses of study data, reviewers found a statistically significant benefit of LLLT on pain outcomes, but not disability or ROM. For the primary outcome (post-treatment pain scores) in a meta-analysis of all 7 trials, mean VAS scores were significantly lower in the LLLT group than in the placebo group (WMD = -13.57; 95% CI, -17.42 to -9.72). In a meta-analysis of 4 studies reporting the other primary outcome (ODI score) there was no statistically significant difference between the LLLT and placebo groups (WMD = -2.89; 95% CI, -7.88 to 2.29). Outcomes were only reported immediately after treatment.

Chen et al (2022) published a systematic review of RCTs on LLLT for treating nonspecific chronic low back pain compared to placebo.<sup>80</sup> Eleven trials were included that compared LLLT to placebo (N=836 patients); seven of these trials assessed LLLT alone compared to placebo and 4 trials assessed LLLT plus acupuncture compared to placebo. For the overall risk of bias in LLLT trials, 8 were identified as low risk, 2 as having some concerns, and 1 as high risk. The primary outcomes of interest were changes from baseline in pain scores, measured by VAS, and disability measured by the ODI score. In pooled analyses, reviewers found a significant reduction in pain scores with all LLLT interventions compared to placebo posttreatment (SMD, -0.22; 95% CI, -0.38 to -0.05) and in disability scores for trials comparing LLLT therapy alone compared to placebo (SMD, -0.50; 95% CI, -0.79 to -0.21). In trials comparing LLLT plus acupuncture to placebo, there was no significant difference in disability scores posttreatment (SMD, 0.10; 95% CI, -0.15 to 0.35).

**Table 9. Comparison of Trials/Studies Included in Systematic Reviews & Meta-Analysis for Low Back Pain**

Study	Glazov et al (2016) <sup>74</sup> ,	Huang et al (2015) <sup>75</sup> ,	Chen et al (2022) <sup>76</sup> ,
Alayat et al (2014) <sup>81</sup> ,	●		
Ay et al (2010) <sup>82</sup> ,	●		●
Basford et al (1999) <sup>82</sup> ,	●	●	●
Djavid et al (2007) <sup>84</sup> ,	●	●	●
Glazov et al (2009) <sup>85</sup> ,	●		●

Glazov et al (2014) <sup>86,</sup>	●		●
Klein et al (1990) <sup>87,</sup>	●	●	
Konstantinovic et al (2011) <sup>88,</sup>	●		
Lin et al (2012) <sup>89,</sup>	●		●
Okamoto et al (1989) <sup>90,</sup>	●		
Ruth et al (2010) <sup>91,</sup>	●		
Soriano et al (1998) <sup>91,</sup>	●	●	
Umegaki et al (1989) <sup>93,</sup>	●		
Vallone et al (2014) <sup>94,</sup>	●	●	
Wallace et al (1996) <sup>95,</sup>	●		
Gur et al (2003) <sup>96,</sup>		●	●
Hsieh et al (2014) <sup>97,</sup>		●	
de Carvalho et al (2016) <sup>98,</sup>			●
Tantawy et al (2019) <sup>99,</sup>			●
Nambi et al (2018) <sup>100,</sup>			●
Shin et al (2015) <sup>101,</sup>			●

**Table 10. Systematic Reviews & Meta-Analysis Characteristics for Low Back Pain**

Study	Dates	Trials	Participants	N (Range)	Design	Duration
Glazov et al (2016) <sup>78</sup>	1989-2014	15	Non-pregnant adults with CLBP	1039 (20-144)	RCT	NR
Huang et al (2015) <sup>79</sup>	1990-2014	7	Patients with nonspecific CLBP	394 (20-100)	RCT	NR
Chen et al (2022) <sup>80</sup>	1999-2020	11	Patients with nonspecific CLBP	836 (30-220)	RCT	NR

CLBP: chronic low back pain; NR: not reported; RCT: randomized controlled trial.

**Table 11. Systematic Reviews & Meta-Analysis Results for Low Back Pain**

Study	Pain	Disability Score
Glazov et al (2016) <sup>78</sup>	VAS (LLLT vs. Control)	NR
WMD	-0.79	
95% CI	-1.22 to -0.36	
$I^2$	70%	

Huang et al (2015) <sup>79</sup>	VAS (LLLT vs. Control)	ODI (LLLT vs. Control)
WMD	-13.57	-12.0
95% CI	-17.42 to -9.72	-2.02 to -21.98
$I^2$	0%	77.6%
Chen et al (2022) <sup>80</sup>	VAS (LLLT + acupuncture vs. Control)	ODI (LLLT vs. Control; LLLT + acupuncture vs. Control)
SMD	-0.22	-0.50; 0.10
95% CI	-0.38 to -0.05	-0.79 to -0.21; -0.15 to 0.35
P-value	.009	.0007; .44
$I^2$	24%	11%; 0%

CI: confidence interval; LLLT: low-level laser therapy; NR: not reported; ODI: Oswestry Disability Index; SMD: standard mean difference; VAS: visual analog scale; WMD: weighted mean difference;.

### Randomized Controlled Trials

In a double-blind RCT, Koldas Dogan et al (2017) compared the effectiveness of 2 laser therapy regimens on pain, lumbar ROM, and functional capacity in patients with chronic low back pain.<sup>102</sup> This trial assessed 49 patients with chronic low back pain who were randomized to a hot pack and the 2 different laser therapies for a total of 15 sessions. A series of assessments were conducted before and after treatment, including a modified Schober test; right and left lateral flexion measurements; VAS; and a modified ODI. After treatment, both groups saw a significant improvement in VAS, ODI, and lumbar ROM ( $p < 0.05$ ). However, group 2 saw significantly better results in lateral flexion measurements and ODI scores ( $p < 0.05$ ). Trial limitations included: (1) the short duration of follow-up; and (2) use of hot packs, which might have biased the pain measurements. No superiority was found for 1 laser treatment over the other regarding pain relief; however, regarding functionality, patients might find the Helium-Neon laser to be superior.

### Section Summary: Low Back Pain

The literature on LLLT for low back pain consists of RCTs and several systematic reviews of RCTs. Meta-analyses found that LLLT resulted in significantly greater reductions in pain scores and global assessment scores than a placebo control in the immediate post-treatment setting. Meta-analyses also found that other outcomes (eg, disability index, ROM) were significantly better immediately after treatment with active versus placebo LLLT, though not at longer-term follow-up.

## OSTEOARTHRITIC KNEE PAIN

### Clinical Context and Therapy Purpose

The purpose of LLLT in individuals who have osteoarthritic knee pain is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does the use of LLLT improve the net health outcome in individuals who have osteoarthritic knee pain?

The following PICO was used to select literature to inform this review.

**Populations**

The relevant population of interest is individuals who have osteoarthritic knee pain. Also called degenerative arthritis, osteoarthritis (OA) is the most common type of arthritis, which occurs when the cartilage in the knee deteriorates with use and age.

**Interventions**

The therapy being considered is LLLT.

**Comparators**

The following practices are currently being used to treat osteoarthritic knee pain: conservative therapy (eg, physical therapy), medication, and surgery.

**Outcomes**

General outcomes of interest are improvements in functional outcomes and QOL and a reduction in symptoms and treatment-related morbidity. The effects of LLLT to promote healing are expected to occur from weeks to months.

**Study Selection Criteria**

See the information under the first indication.

**REVIEW OF EVIDENCE**

**Systematic Review**

Several RCTs and systematic reviews of RCTs have evaluated LLLT for treatment of knee OA, coming to inconsistent conclusions.<sup>103,104</sup> The most inclusive and up-to-date of these was published by Stausholm et al (2019) and compared LLLT with placebo for knee OA patients.<sup>105</sup> To be eligible for inclusion, trials had to report pain, disability, or QOL. A total of 22 trials (N=1063) met eligibility criteria. Interventions included between 5 to 16 sessions of LLLT or sham LLLT. A total of 9 included studies used a non-recommended dose of LLLT, which had a mean treatment duration of 3.7 weeks. The mean treatment duration was 3.53 weeks in studies using appropriate dosing. The primary outcome was posttreatment pain measured by a 0 to 100 mm VAS score at end of treatment and follow-up (1 to 12 weeks). The mean difference in VAS score was statistically significant favoring LLLT over placebo at end of treatment (14.23 mm; 95% CI, 7.31 to 21.14;  $I^2=93\%$ ) and at follow up (15.92 mm; 95% CI, 6.47 to 25.37;  $I^2=93\%$ ). There was high heterogeneity for the primary outcome, possibly due to differences in follow-up time period. Risk of bias appeared low. Only 1 study included QOL data, and therefore no QOL meta-analysis was performed.

**Table 12. Trials/Studies Included in Systematic Reviews & Meta-Analysis for Osteoarthritic Knee Pain**

Study	Stausholm et al (2019) <sup>101</sup>
Al Rashoud et al (2014) <sup>106</sup>	●
Alfredo et al (2011, 2018) <sup>107,108</sup>	●

Alghadir et al (2014) <sup>109</sup>	●
Bagheri et al (2011) <sup>110</sup>	●
Bülow et al (1994) <sup>111</sup>	●
Delkhosh et al (2018) <sup>112</sup>	●
Fukuda et al (2011) <sup>113</sup>	●
Gur et al (2003) <sup>114</sup>	●
Gur and Oktayoglu (unpublished)	●
Gworys et al (2012) <sup>115</sup>	●
Hegedűs et al (2009) <sup>116</sup>	●
Helianthi et al (2016) <sup>117</sup>	●
Hinman et al (2014) <sup>118</sup>	●
Jensen et al (1987) <sup>119</sup>	●
Kheshie et al (2014) <sup>120</sup>	●
Koutenaei et al (2017) <sup>121</sup>	●
Mohammed et al (2018) <sup>122</sup>	●
Nambi et al (2016) <sup>123</sup>	●
Nivbrant et al (1992) <sup>124</sup>	●
Rayegani et al (2012) <sup>125</sup>	●
Tascioglu et al (2004) <sup>127</sup>	●
Youssef et al (2016) <sup>128</sup>	●

**Table 13. Systematic Reviews & Meta-Analysis Characteristics for Osteoarthritic Knee Pain**

Study	Dates	Trials	Participants	N (Range)	Design	Duration
Stausholm et al (2019) <sup>105</sup>	1987-2018	22	Patients with OA knee pain	1063 (12-71)	RCT	1-12 weeks

OA; osteoarthritis

**Table 14. Systematic Reviews & Meta-Analysis Results for Osteoarthritic Knee Pain**

Study	VAS (LLLT vs. placebo)	Disability (LLLT vs. placebo)
-------	------------------------	-------------------------------

Stausholm et al (2019) <sup>105</sup>		
At end of therapy		
n	816	617
MD	14.23 mm	0.59
95% CI	7.31 to 21.14	0.23 to 0.86
I <sup>2</sup> (%)	93	57
At follow-up (week 1-12)		
n	581	289
MD	15.92 mm	0.66
95% CI	6.47 to 25.37	0.23 to 1.09
I <sup>2</sup>	93	67

CI: confidence interval; LLLT: low level laser therapy; MD: mean difference; VAS: visual analogue scale; vs: versus

### Section Summary: Osteoarthritic Knee Pain

The literature on LLLT for OA includes RCTs and multiple systematic reviews of RCTs. One of the more recent systematic reviews, which pooled study findings, did not find that LLLT significantly reduced pain and improved disability compared with a sham intervention; however, there was high heterogeneity between studies, and individual studies are limited by small sample size and inconsistent timing of follow-up.

## HEEL PAIN

### Clinical Context and Therapy Purpose

The purpose of LLLT in individuals who have heel pain (ie, Achilles tendinopathy, plantar fasciitis) is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does the use of LLLT improve the net health outcome in individuals who have heel pain (ie, Achilles tendinopathy, plantar fasciitis)?

The following PICO was used to select literature to inform this review.

### **Populations**

The relevant population of interest is individuals who have heel pain, which can include Achilles tendinopathy, plantar fasciitis, and heel bursitis, etc.

### **Interventions**

The therapy being considered is LLLT.

### **Comparators**

The following practices are currently being used to treat heel pain: conservative therapy (eg, physical therapy), medication, and surgery.

## **Outcomes**

The general outcomes of interest are improvements in functional outcomes and QOL and a reduction in symptoms and treatment-related morbidity. The effects of LLLT to promote healing are expected to occur from weeks to months.

## **Study Selection Criteria**

See the information under the first indication.

## **REVIEW OF EVIDENCE**

### **ACHILLES TENDINOPATHY**

#### **Randomized Controlled Trial**

Stergioulas et al (2008) randomized 52 recreational athletes with chronic Achilles tendinopathy symptoms to an 8-week (12-session) program of eccentric exercises with LLLT or with sham LLLT.<sup>126</sup> By intention-to-treat (ITT) analysis, results for the primary outcome of pain during physical activity assessed on a VAS were significantly lower in the exercise with LLLT group at 4 ( $p<.001$ ), 8 ( $p<.001$ ), and 12 weeks ( $p=.007$ ) after randomization.

Tumilty et al (2012) reported on a randomized, double-blinded, sham-controlled trial of LLLT as an adjunct to 3 months of exercise training in 40 patients with Achilles tendinopathy.<sup>128</sup> Active or sham LLLT was administered 3 times a week for 4 weeks, and exercises performed twice daily for 12 weeks. The primary outcome was the Victorian Institute of Sport Assessment-Achilles questionnaire (VISA-A) at 12 weeks. The only significant difference between the groups using intention-to-treat analysis was at 4 weeks for the Victorian Institute of Sport Assessment-Achilles Questionnaire scores, and that difference favored the sham control group. The VISA-A and pain numeric rating scale scores did not differ significantly between the active and sham groups at 12-week or 1-year follow-ups.

### **PLANTAR FASCIITIS**

#### **Systematic Reviews**

Wang et al (2019) published a systematic review and meta-analysis of 6 RCTs comparing LLLT (alone or combined with other interventions) and controls (placebo or other interventions).<sup>129</sup> A total of 315 adults with plantar heel pain or plantar fasciitis were included in the analysis. Compared with controls, VAS was significantly reduced after treatment (SMD, -0.95; 95% CI -1.20 to -0.70;  $p<.001$ ), as well as remaining significantly better at 3 months (SMD, -1.13; 95% CI -1.53 to -0.72;  $p<.001$ ). The meta-analysis was limited by the small number of studies included, small sample size, and insufficient data for longer-term outcomes.

Guimaraes et al (2022) published a systematic review and meta-analysis of 14 studies ( $N=817$ ) comparing LLLT (alone or combined with other interventions) and controls (placebo and other interventions).<sup>130</sup> Compared to the placebo group, LLLT improved pain in the short term of 0 to 6 weeks (4 studies,  $n=234$ ; moderate-quality evidence; MD, -2.28; 95% CI, -2.58 to -1.97;  $p<.00001$ ;  $I^2=0\%$ ). No significant difference in short-term disability was found for individuals in the LLLT group compared to the placebo group. Compared to the conventional rehabilitation alone group, LLLT combined with conventional rehabilitation improved pain in the

short term of 0 to 6 weeks (2 studies, n=90; moderate-quality evidence; MD, -2.01; 95% CI, -2.89 to -1.13;  $p<.00001$ ;  $I^2=0\%$ ). However, compared to ESWT, LLLT did not significantly reduce pain intensity in the short term (4 studies, n=175; low-quality evidence; MD, 0.45; 95% CI, -2.0 to 2.9;  $p=.72$ ;  $I^2=94\%$ ). The meta-analysis was limited by insufficient data for longer-term outcomes, the lack of multicenter studies, and lack of a large sample. Additionally, the quality of evidence for the outcome disability were determined to be low.

### **Randomized Controlled Trials**

A double-blind RCT by Macias et al (2015) assessed 69 patients with unilateral chronic plantar fasciitis and chronic heel pain of 3 months or longer that was unresponsive to conservative treatments (eg, rest, stretching, physical therapy).<sup>131</sup> Patients were randomized to twice weekly treatment for 3 weeks of LLLT or sham treatment. The primary efficacy outcome (reduction of heel pain pre- to posttreatment) differed significantly between groups ( $p<.001$ ). Mean VAS scores decreased from 69.1 to 39.5 in the LLLT group and from 67.6 to 62.3 in the sham group. The difference in the Foot Function Index scores did not differ significantly between groups.

An RCT on LLLT for plantar fasciitis was reported by Kiritsi et al (2010).<sup>132</sup> The trial was double-blind and sham-controlled and assessed 30 patients. Twenty-five (83%) patients completed the study, with treatment 3 times per week over 6 weeks. At baseline, plantar fascia thickness, measured by ultrasound, was significantly greater in symptomatic feet (5.3 mm) compared with asymptomatic feet (3.0 mm). Plantar fascia thickness decreased in both the LLLT and the sham groups during the trial. Although plantar fascia thickness after 6 weeks of treatment did not differ significantly between groups (3.6 mm in LLLT vs. 4.4 mm in sham), there was a significant between-groups difference in the reduction in thickness (1.7 mm LLLT vs. 0.9 mm sham). After night rest or daily activities, VAS scores improved significantly more in the LLLT group (59% improvement) than in the sham group (26% improvement). At baseline, pain after daily activities was rated as 67 out of 100 by both groups. At the end of treatment, VAS scores for daily activities were rated as 28 out of 100 for LLLT and 50 out of 100 for sham.

Cinar et al (2018) conducted a prospective single-blinded RCT investigating combination therapy consisting of LLLT plus exercise and orthotic care versus orthotic care alone in persons with plantar fasciitis.<sup>132</sup> Forty-nine individuals were randomized to LLLT (n=27) or a control therapy (n=22). Each person performed a home exercise routine and received orthotic care; persons in the LLLT group received treatment 3 times a week for a total of 10 sessions. The function subscale of the American Orthopedic Foot and Ankle Society Score, a VAS, and the 12-minute walk test were used to measure progress. Scores were recorded at baseline, 3 weeks, and 3 months after treatment. At week 3, both groups saw a significant improvement in American Orthopedic Foot and Ankle Society total score (LLLT,  $p<.001$ ; control,  $p=.002$ ). However, at the 3-month follow-up, only the LLLT group progressed as assessed on the American Orthopedic Foot and Ankle Society total score ( $p=.04$ ). At all check-ins, the group scores for the 12-minute walk test were comparable. Both groups showed significant pain reductions at the 3-month follow-up (LLLT,  $p<.001$ ; control,  $p=.01$ ); however, the LLLT group had a more significant reduction in pain at month 3 ( $p=.03$ ). Thus, reviewers concluded that combination therapy plus LLLT was more effective in reducing pain and improving function for patients with plantar fasciitis than orthotic care alone. Limitations included a lack of a control

group, which would have accounted for the natural progression of recovery in patients with plantar fasciitis.

**Table 15. Summary of Key RCT Characteristics**

Study; Trial	Countries	Sites	Dates	Participants	Interventions	
					Active	Comparator
Kiritisi et al (2010) <sup>132</sup>	Greece	NR	2006-2007	Patients with unilateral idiopathic PF	LLLT (n=15)	Placebo (n=15)
Macias et al (2015) <sup>131</sup>	US	NR	2011-2013	Patients unilateral chronic PF	LLLT (n=37)	Placebo (n=32)
Cinar et al (2018) <sup>133</sup>	Turkey	NR	2012-2013	Patients with PF	LLLT (n=27)	Control (n=22)

LLLT: low-level laser therapy; NR: not reported; PR: plantar fasciitis.

**Table 16. Summary of Key RCT Results**

Study	Pain	Plantar Fascia Thickness	AOFAS-F [95%CI]
Kiritisi et al (2010) <sup>132</sup>	<b>VAS (Difference from Baseline)</b>	<b>(Difference from Baseline)</b>	NR
LLLT	40±20.3	1.667±0.547	
Placebo	18±8.9	0.920±0.220	
P-value	.001	.007	
Macias et al (2015) <sup>131</sup>	<b>FFI scores (Baseline; Endpoint)</b>	<b>NR</b>	<b>NR</b>
LLLT	111.9±34.2; 82.0±43.6		
Placebo	110.8±32.3; 86.1±43.2		
P-value	.89; .70		
Cinar et al (2018) <sup>131</sup>	<b>VAS (Baseline; 3 months) [95% CI]</b>	<b>NR</b>	
LLLT	6.13; 1.72 [5.41 to 6.85; 0.78 to 2.67]		44.16; 49.95 [42.58 to 45.74; 48.45 to 51.45]
Placebo	5.49; 3.67 [4.67 to 6.31; 2.56 to 4.77]		45.55; 47.78 [43.75 to -47.34; 46.07 to 49.49]

AOFAS: American Orthopedic Foot and Ankle Society Score; CI: confidence interval; RCT: randomized controlled trial; FFI: foot function index; LLLT: low-level laser therapy; VAS: visual analog scale.

Table 17 displays notable limitations identified in each study.

**Table 17. Study Design and Conduct Limitations**

Study	Allocation <sup>a</sup>	Blinding <sup>b</sup>	Selective Reporting <sup>c</sup>	Follow-Up <sup>d</sup>	Power <sup>e</sup>	Statistical <sup>f</sup>
Kiritisi et al (2010) <sup>132</sup>	3. Allocation concealment unclear	3. Blinding of outcome assessment unclear				
Macias et al (2015) <sup>131</sup>						
Cinar et al (2018) <sup>133</sup>		3. Blinding of outcome assessment unclear				

The evidence limitations stated in this table are those notable in the current review; this is not a comprehensive limitations assessment.

<sup>a</sup> Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear;

4. Inadequate control for selection bias.

<sup>b</sup> Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

<sup>c</sup> Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

<sup>d</sup> Follow-Up key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

<sup>e</sup> Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

<sup>f</sup> Statistical key: 1. Intervention is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Intervention is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

## **Section Summary: Heel Pain**

Multiple sham-controlled randomized trials have evaluated LLLT for heel pain (Achilles tendinopathy, plantar fasciitis). but findings were inconsistent. One RCT compared LLLT plus therapy with orthotic care alone, and while a significant advantage was observed in LLLT treatment, LLLT treatment was used as a combination therapy. Findings from meta-analyses were conflicting. A meta-analysis of Achilles tendinopathy trials found no benefit in pain reduction with LLLT with the exception of at 2 months of follow-up reported in a single trial. A second meta-analysis did find short-term (0 to 6 week) pain improvement in patients receiving LLLT compared to placebo or in combination with conventional rehabilitation, but did not find pain improvement with LLLT compared to ESWT. None of the studies presented long-term follow-up data. Given all factors, further studies are needed to validate the technology.

## **Rheumatoid Arthritis (RA)**

### **Clinical Context and Therapy Purpose**

The purpose of LLLT in individuals who have rheumatoid arthritis (RA) is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does the use of LLLT improve the net health outcome in individuals who have RA?

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals who have RA, a debilitating autoimmune condition that can affect most joints in the body.

### ***Interventions***

The therapy being considered is LLLT.

### ***Comparators***

The practices are currently being used to treat RA: conservative therapy (eg, exercise) and medication, including nonsteroidal anti-inflammatory drugs, steroids, disease-modifying antirheumatic drugs, and biologic agents.

## **Outcomes**

General outcomes of interest are improvements in functional outcomes and QOL and a reduction in symptoms and treatment-related morbidity. The effects of LLLT to promote healing are expected to occur from weeks to months.

## **Study Selection Criteria**

See the information under the first indication.

## **REVIEW OF EVIDENCE**

### **Systematic Review**

A Cochrane review by Brosseau et al (2005) included 5 placebo-controlled randomized trials and found that, relative to a separate control group, LLLT reduced pain by 1.10 points on VAS compared with placebo, reduced morning stiffness duration by 27.5 minutes, and increased tip-to-palm flexibility by 1.3 cm.<sup>134</sup> Other outcomes, such as functional assessment, ROM, and local swelling, did not differ between groups. For rheumatoid arthritis, relative to a control group using the opposite hand (1 study), difference was observed between the control and treatment hand for morning stiffness duration, and no significant improvement in pain relief. Reviewers noted that “despite some positive findings, this meta-analysis lacked data on how LLLT effectiveness is affected by 4 important factors: wavelength, treatment duration of LLLT, dosage, and site application over nerves instead of joints.”

A randomized, double-blind placebo-controlled trial comparing outcomes for pain reduction and improvement in hand function in 82 patients with rheumatoid arthritis treated with LLLT or placebo laser was reported by Meireles et al (2010).<sup>135</sup> There were no statistically significant differences between groups for most outcome measurements, including the primary variables, though a few measures significantly favored either the active or placebo treatment. Reviewers concluded that LLLT at the dosage used in the trial was ineffective for treating RA.

### **Section Summary: Rheumatoid Arthritis**

A Cochrane review of 5 placebo-controlled RCTs found statistically significant improvement of LLLT on some outcomes (eg, VAS) but not others (eg, functional assessment). A 2010 RCT, published after the Cochrane review, did not find that LLLT was significantly better than a placebo treatment for most outcomes.

## **BELL PALSY (FACIAL NERVE PALSY)**

### **Clinical Context and Therapy Purpose**

The purpose of LLLT in individuals who have Bell palsy is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does the use of LLLT improve the net health outcome in individuals who have Bell palsy?

The following PICO was used to select literature to inform this review.

### **Populations**

The relevant population of interest is individuals who have Bell palsy, a condition in which the muscles on 1 side of the face become weak or paralyzed caused by trauma to the seventh cranial nerve.

## **Interventions**

The therapy being considered is LLLT.

## **Comparators**

The following practices are currently being used to treat Bell palsy: conservative therapy (eg, exercise) and medications, including corticosteroids and antiviral drugs.

## **Outcomes**

General outcomes of interest are improvements in functional outcomes and QOL and a reduction in symptoms and treatment-related morbidity. The effects of LLLT to promote healing are expected to occur from weeks to months. Outcomes are assessed using the Facial Disability Index and the House-Brackmann Scale.

## **Study Selection Criteria**

See the information under the first indication.

## **REVIEW OF EVIDENCE**

### **Randomized Controlled Trial**

Alayat et al (2014) reported on a randomized, double-blind, placebo-controlled trial of laser therapy for the treatment of 48 patients with Bell palsy.<sup>136</sup> Facial exercises and massage were given to all patients. Patients were randomized to 1 of 3 groups: high-intensity laser therapy, LLLT, or exercise only. Laser treatment was given 3 times per week to 8 points of the affected side for 6 weeks. At 3 and 6 weeks post-treatment, outcomes were assessed using the Facial Disability Scale and the House-Brackmann Scale. Significant improvements in recovery were seen in both laser therapy groups over exercise alone, with the greatest improvement seen with a high-intensity laser.

Ordahan and Karahan (2017) investigated the efficacy of LLLT when used in combination with traditional facial exercises to treat facial paralysis.<sup>137</sup> Forty-six patients with Bell palsy were randomized to 2 groups: 1 group underwent LLLT plus facial exercise therapy (n=23); the other group underwent facial exercise therapy alone (n=23). Laser therapy was administered 3 times a week for 6 weeks. Patients were evaluated during the treatment and at 3 and 6 weeks post-treatment. The Facial Disability Index was used to evaluate progress. No significant improvement was observed at week 3 in the facial exercise therapy-alone treatment group ( $p<.05$ ), but significant improvement was noted at week 6 ( $p<.001$ ). In the LLLT plus facial exercise therapy group, significant improvement was noted at 3 and 6 weeks ( $p<.001$ ); moreover, improvements in the Facial Disability Index scores in the LLLT plus facial exercise therapy group were significantly greater than those of the facial exercise therapy-alone treatment group at week 3 and week 6 ( $p<.05$ ). Study limitations included lack of long-term follow-up and use of combination therapy, which obscures the contribution of LLLT.

### **Section Summary: Bell Palsy**

One RCT found a significant short-term benefit of LLLT over exercise but long-term outcomes were not available. Another RCT found significant short-term benefit with facial exercise therapy plus LLLT over facial exercise therapy alone, but again, no long-term data were available. The limited evidence on laser therapy for Bell's palsy is insufficient to draw

conclusions. Because Bell's palsy often improves within weeks and may resolve completely within months, it is difficult to isolate specific improvements from laser therapy over the natural resolution of the illness. Also, no sham-controlled trials were available.

## **FIBROMYALGIA**

### **Clinical Context and Therapy Purpose**

The purpose of LLLT in individuals who have fibromyalgia is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does the use of LLLT improve the net health outcome in individuals who have fibromyalgia?

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals who have fibromyalgia, a disorder characterized by widespread musculoskeletal pain often accompanied by fatigue, sleep, memory, and mood issues. Symptoms can begin after a physical trauma, surgery, or infection or, in some cases, gradually accumulate over time without a single triggering event.

Often, fibromyalgia co-exists with other conditions, including irritable bowel syndrome, migraine, interstitial cystitis, and TMJ disorders.

### ***Interventions***

The therapy being considered is LLLT.

### ***Comparators***

The following practice is currently being used to treat fibromyalgia: conservative therapy (eg, exercise) and medications, including pain relievers, antidepressants, and anti-seizure drugs.

### ***Outcomes***

The general outcomes of interest are improvements in functional outcomes and QOL and a reduction in symptoms and treatment-related morbidity. The effects of LLLT to promote healing are expected to occur from weeks to months. Outcomes are measured with the Fibromyalgia Impact Questionnaire (FIQ), the McGill Pain Questionnaire, and a pain VAS.

### **Study Selection Criteria**

See the information under the first indication.

## **REVIEW OF EVIDENCE**

### **Systematic Review**

Honda et al (2018) published a systematic review and meta-analysis of RCTs evaluating pain relief modalities for fibromyalgia.<sup>138</sup> Eleven studies with a total of 498 patients (range, 20 to 80) were included; 5 studies evaluated LLLT and the remainder covered other treatment modalities. Compared with control, LLLT was not associated with a reduction of VAS-measured pain (MD -4.0; 95% CI -23.4 to 15.4;  $p = .69$ ). LLLT showed a significant reduction in

tender points compared with control (MD, -2.21; 95% CI, -3.51 to -0.92;  $I^2=42\%$ ;  $p=.0008$ ) and in the FIQ score (MD, -4.35; 95% CI, -6.69 to -2.01;  $I^2=62\%$ ;  $p=.03$ ). The analysis was limited by its inclusion criteria limited to a pure control group or placebo group for a specific intervention and exclusion of those that used another intervention as a comparator. Several treatment modalities were evaluated and individual pooled results for each intervention had a high degree of heterogeneity.

### **Randomized Controlled Trials**

Several small RCTs evaluating LLLT for fibromyalgia have been published. Ruaro et al (2014) reported on 20 patients randomized to LLLT or sham treatment 3 times a week for 4 weeks (12 total treatments).<sup>138</sup> Outcomes included scores in the Fibromyalgia Impact Questionnaire (FIQ), which measures physical function, ability to work, pain, fatigue and depression; the McGill Pain Questionnaire (MPQ); and a pain VAS. All 3 outcomes were significantly better in the active than with sham LLLT post-treatment. Mean overall FIQ score were 18.6 in the LLLT group and 5.2 in the sham group ( $p=.003$ ). Mean change scores also differed significantly between groups for McGill Pain Questionnaire score ( $p=.008$ ) and VAS score ( $p=.002$ ).

Matsutani et al (2007) randomized 20 patients with fibromyalgia to laser treatment plus stretching exercises or stretching alone.<sup>140</sup> Outcome measures were VAS scores and dolorimetry at tender points, quality of life on the FIQ, and the 36-Item Short-Form Health Survey (SF-36) scores. At the end of treatment, both groups demonstrated pain reductions, higher pain thresholds at tender points (all  $p<.01$ ), lower mean FIQ scores, and higher SF-36 mean scores (all  $p<.05$ ). No significant differences were found between groups.

### **Section Summary: Fibromyalgia**

Few RCTs evaluating LLLT for fibromyalgia are available, which have been included in a systematic review and meta-analysis; the existing trials are small (ie, <25 patients each). One RCT (N=20 patients) found significantly better outcomes with LLLT than with sham, and another RCT (N=20 patients) did not find statistically-significant between-group differences for similar outcomes. Additional RCTs with sufficient numbers of patients are needed.

## **CHRONIC NONHEALING WOUNDS**

### **Clinical Context and Therapy Purpose**

The purpose of LLLT in individuals who have chronic non-healing wounds is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does the use of LLLT improve the net health outcome in individuals who have chronic non-healing wounds?

The following PICO was used to select literature to inform this review.

### **Populations**

The relevant population of interest is individuals who have chronic non-healing wounds: wounds that do not improve after 4 weeks or heal in 8 weeks. These include diabetic foot ulcers, venous-related ulcerations, non-healing surgical wounds, and pressure ulcers. They are often found on the feet, ankles, heels, calves and on the hips, thighs, and buttocks of those who cannot walk.

## **Interventions**

The therapy being considered is LLLT.

## **Comparators**

The following practice is currently being used to treat chronic nonhealing wounds: standard wound care, including wound debridement, compression therapy, and antibacterial treatment.

## **Outcomes**

The outcome of interest is complete healing or healing to a degree that permits a procedure that results in complete healing. The effects of LLLT to promote healing are expected to occur from weeks to months.

## **Study Selection Criteria**

See the information under the first indication.

## **REVIEW OF EVIDENCE**

### **Systematic Review**

An evidence assessment by Samson et al (2004), which evaluated vacuum-assisted and low-level laser wound therapies for treatment of chronic nonhealing wounds and was prepared for the Agency for Healthcare Research and Quality, was based on 11 studies of LLLT.<sup>138</sup> It stated: "The best available trial [of low-level laser wound therapy] did not show a higher probability of complete healing at 6 weeks with the addition of low-level laser compared with sham laser treatment added to standard care. Study weaknesses were unlikely to have concealed existing effects. Future studies may determine whether different dosing parameters or other laser types may lead to different results."

A Cochrane review by Chen et al (2014) evaluated RCTs on light therapy, including phototherapy, ultraviolet, and laser, for pressure ulcers.<sup>142</sup> The few trials available for analysis were of small size and very low-quality. Reviewers found the available evidence overall insufficient to conclude whether light therapy is effective on pressure ulcers.

Machado et al (2017) also published a systematic review evaluating the treatment of pressure ulcers with LLLT.<sup>143</sup> Reviewers identified 4 studies meeting eligibility requirements (N=210 patients). Outcomes were the ulcer area, healing rate, and overall healing rate. Two of the 4 studies used LLLT with a single wavelength<sup>144,145</sup>; and the other 2 used LLLT with probe cluster, which employs the simultaneous assimilation of different types of diodes and wavelengths.<sup>146,147</sup> In the study that employed the 658 nm wavelength, reviewers found that particular frequency reduced pressure ulcers by 71%. The other wavelengths did not produce any significant findings related to the study outcome; moreover, the studies using the probe cluster technique were also not successful in producing significant findings. While studies should be conducted to investigate further the success found in single wavelength at 658 nm, at this time there is insufficient evidence to suggest LLLT can significantly benefit patients with pressure ulcers.

Li et al (2018) published a systematic review and meta-analysis of 7 RCTs (N=194 patients) evaluating LLLT as a treatment for a diabetic foot ulcer.<sup>148</sup> Ulcer area was significantly reduced with LLLT compared with control (WMD, 34.18; 95% CI, 19.38 to 48.99; p<.001), and the

complete healing rate significantly improved with LLLT (odds ratio (OR), 6.72; 95% CI, 1.99 to 22.64;  $p=.002$ ). The analysis was limited by the number of studies included and small sample size, and by each study having different parameters, demographic information, ulcer characteristics, follow-up time, and treatment period.

### **Section Summary: Chronic Nonhealing Wounds**

Multiple systematic reviews of the literature did not find sufficient evidence from controlled studies demonstrating that LLLT is effective for wound healing.

## **LYMPHEDEMA**

### **Clinical Context and Therapy Purpose**

The purpose of LLLT in individuals who have lymphedema is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does the use of LLLT improve the net health outcome in individuals who have lymphedema?

The following PICO was used to select literature to inform this review.

### **Populations**

The relevant population of interest is individuals who have lymphedema or swelling in 1 or both arms and legs. It is commonly caused by the removal of a lymph node. The resulting blockage of the lymphatic system prevents lymph fluid from draining well, leading to fluid build-up and swelling. Other symptoms can include heaviness or tightness in the affected limb, restricted range of motion, aching or discomfort, recurring infections, and dermal fibrosis. Risk factors for developing lymphedema after cancer from cancer treatment or from other secondary causes can include older age, obesity, and rheumatoid or psoriatic arthritis.

### **Interventions**

The therapy being considered is LLLT.

### **Comparators**

The following practices are currently being used to treat lymphedema: conservative care (eg, exercise), pneumatic compression, and complete decongestive therapy.

### **Outcomes**

General outcomes of interest are improvements in functional outcomes and QOL and a reduction in symptoms and treatment-related morbidity. The effects of LLLT to promote healing are expected to occur from weeks to months.

### **Study Selection Criteria**

See the information under the first indication.

## **REVIEW OF EVIDENCE**

### **Systematic Review**

Several systematic reviews of RCTs and observational studies have been published. For example, Smoot et al (2015) published a systematic review of studies on the effect of LLLT on

symptoms in women with breast cancer-related lymphedema.<sup>149</sup> Reviewers identified 9 studies, 7 RCTs and 2 single-group studies. Three studies had a sham control group, 1 used a waitlist control, and 3 compared LLLT with an alternative intervention (eg, intermittent compression). Only 3 studies had blinded outcomes assessments and, in 3 studies, participants were blinded. A pooled analysis of 4 studies found significantly greater reductions in upper-extremity volume with LLLT than with the control condition (pooled effect size, -0.62; 95% CI, -0.97 to -0.28). Only 2 studies were suitable for a pooled analysis of the effect of LLLT on pain. This analysis did not find a significant difference in pain levels between LLLT and control (pooled effect size, -1.21; 95% CI, -4.51 to 2.10).

Omar et al (2012) published a qualitative systematic review of LLLT for the management of breast cancer-related lymphedema.<sup>150</sup> They selected 8 studies (N=230 patients) for their review. Five studies were graded as Sackett evidence level II (small randomized trial with high false-positive or false-negative errors), 2 were graded as level III (nonrandomized comparative study), and 1 study was graded as level V evidence (case series). Reviewers noted major methodologic flaws and little uniformity in trial designs.

### **Randomized Controlled Trial**

One of the larger double-blind RCTs was published by Omar et al (2011); it reported on 50 patients with postmastectomy lymphedema.<sup>150</sup> The average length of time that patients had swelling was 14 months (range, 12 to 36 months). They were treated with active or sham laser 3 times a week for 12 weeks over the axillary and arm areas. Also, all participants were instructed to perform daily arm exercises and to wear a pressure garment. Limb circumference, shoulder mobility, and grip strength were measured before treatment and at 4, 8, and 12 weeks. Limb circumference declined over time in both groups, with significantly greater reductions in the active laser group at 8 (20.0 cm vs. 16.4 cm), 12 (29 cm vs. 21.8 cm), and 16 (31 cm vs. 2 cm) weeks. Shoulder flexion and abduction were significantly better in the active laser group at 8 and 12 weeks. Grip strength was significantly better in the active laser group after 12 weeks (26.2 kg vs. 22.4 kg). The durability of these effects was not assessed.

### **Section Summary: Lymphedema**

Several systematic reviews of RCTs and observational studies found methodologic flaws in the available studies and collectively these studies did not consistently report better outcomes in patients receiving LLLT versus a control condition for treatment of lymphedema.

## **SUMMARY OF EVIDENCE**

### **Oral Mucositis**

For individuals who have increased risk of oral mucositis due to some cancer treatments (eg, chemotherapy, radiotherapy) and/or hematopoietic cell transplantation who receive LLLT, the evidence includes systematic reviews. Relevant outcomes are symptoms, morbid events, quality of life, and treatment-related morbidity. Several systematic reviews of RCTs have found better outcomes with LLLT used to prevent oral mucositis than with control treatments. Results have consistently supported a reduction in severe oral mucositis in patients undergoing chemotherapy, HCT, radiotherapy, and chemoradiotherapy. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

## **Musculoskeletal and Neurologic Disorders**

For individuals who have carpal tunnel syndrome who receive LLLT, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life and treatment-related morbidity. Both a 2016 systematic review and a TEC Assessment (2010) did not find sufficient evidence from RCTs that LLLT improves outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have neck pain who receive LLLT, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. A 2013 systematic review identified 17 trials, most of which were considered low-quality. Only 2 trials were considered moderate-quality, and they found that LLLT led to better outcomes than placebo for chronic neck pain. A TEC Assessment (2010) found conflicting evidence. Additionally, laser types, application dosages, and treatment schedules vary in the available evidence and require further study. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have subacromial impingement syndrome who receive LLLT, the evidence includes RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Most trials did not show a significant benefit of LLLT compared with sham treatment or with an alternative intervention (eg, exercise). The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have adhesive capsulitis who receive LLLT, the evidence includes RCTs and a systematic review. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. A Cochrane review evaluating treatments for adhesive capsulitis identified 2 RCTs assessing LLLT. Due to the small number of trials and study limitations, reviewers concluded that the evidence was insufficient to permit conclusions about the effectiveness of LLLT for adhesive capsulitis. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have temporomandibular joint pain who receive LLLT, the evidence includes RCTs and several systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Meta-analyses of RCTs had mixed findings. A 2021 meta-analysis, which included 33 placebo-controlled randomized trials, found a statistically significant impact of LLLT on pain scores and improved functional outcomes (eg, mouth opening); however, heterogeneity was high among included trials. Furthermore, RCTs have not compared the impact of LLLT with physical therapy. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have low back pain who receive LLLT, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Meta-analyses of RCTs found that LLLT resulted in a significantly greater reduction in pain scores and global assessment scores than a placebo control in the immediate post-treatment setting. Meta-analyses also found that other outcomes (eg, disability index, range of motion) were significantly better immediately after treatment with active rather

than placebo LLLT, but not at longer term follow-up. The evidence is insufficient to determine the technology results in an improvement in the net health outcome.

For individuals who have osteoarthritic knee pain who receive LLLT, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. A 2020 systematic review, which pooled study findings, found that LLLT significantly reduced pain or improved functional outcomes compared with a sham intervention; however, the study was limited by high heterogeneity and inconsistency between regimens and follow-up duration. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have heel pain (ie, Achilles tendinopathy, plantar fasciitis) who receive LLLT, the evidence includes RCTs and a systematic review. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Findings of sham-controlled randomized trials were inconsistent, and RCTs lacked long-term follow up. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have rheumatoid arthritis who receive LLLT, the evidence includes RCTs and a systematic review. The relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. A systematic review of RCTs found an inconsistent benefit of LLLT for a range of outcomes. A 2010 RCT, published after the systematic review, did not find that LLLT was significantly better than a placebo treatment on most outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have Bell palsy who receive LLLT, the evidence includes a systematic review of 4 RCTs, with 2 RCTs reported in English. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. One RCT found significant short-term benefit of LLLT over exercise. Longer-term outcomes (>6 weeks) were not available. Because Bell's palsy often improves within weeks and may completely resolve within months, it is difficult to isolate specific improvements from laser therapy over the natural resolution of the illness. Also, no sham-controlled trials are available. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have fibromyalgia who receive LLLT, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. The RCTs evaluating LLLT for treatment of fibromyalgia are small (ie, <25 patients each). One RCT (N=20 patients) found significantly better outcomes with LLLT than with sham, while another (N=20 patients) did not find statistically significant between-group differences for similar outcomes. Additional RCTs with sufficient numbers of patients are needed to establish the efficacy of LLLT for fibromyalgia. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## **Wound Care and Lymphedema**

For individuals who have chronic nonhealing wounds who receive LLLT, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. The few existing RCTs tend to have small sample sizes and potential risk of bias. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have lymphedema who receive LLLT, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Multiple systematic reviews detected methodologic flaws in the available studies and did not consistently find better outcomes for patients receiving LLLT than those receiving a control condition for treatment of lymphedema. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

## **Summary of Evidence for HPLT**

For individuals treated with HPLT to reduce pain or improve functioning in various musculoskeletal conditions the evidence includes two studies. In one study authors concluded the technology when compared to conventional treatment did not produce greater pain relief or improvements in function. This is contradiction to the results of the other study where authors concluded the technology did increase pain relief and functioning when compared to conventional treatment. More research is needed because of these conflicting results. The evidence is therefore insufficient to determine that the technology results in an improvement of net health outcomes.

## **SUPPLEMENTAL INFORMATION**

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

### **Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

### **Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology**

In 2017, the Mucositis Prevention Guideline Development Group published guidelines on preventing oral and oropharyngeal mucositis in children undergoing hematopoietic cell transplantation.<sup>151</sup> The guidelines were based on an evidence review consisting of randomized controlled trials that evaluated interventions such as cryotherapy and low-level laser therapy (LLLT). The guidelines suggested that LLLT could be offered to children but classified this recommendation as weak.

In 2020, the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology published joint guidelines on the management of mucositis

secondary to cancer therapy.<sup>152</sup> For the prevention of oral mucositis, the 2 associations recommended the following treatments, based on level 1 evidence: LLLT in patients undergoing radiotherapy with chemotherapy for head and neck cancer; LLLT in patients receiving hematopoietic cell transplantation conditioned with high-dose chemotherapy with or without total body irradiation; recombinant human keratinocyte growth factor-1 in patients receiving high-dose chemotherapy and total body irradiation, followed by autologous cell transplantation for hematologic malignancy; and benzydamine mouthwash in patients with head and neck cancer receiving moderate-dose radiotherapy without concomitant chemotherapy.

Additionally, numerous treatments were recommended for the prevention of oral mucositis based on level II evidence, including LLLT in patients undergoing radiotherapy, without concomitant chemotherapy, for head and neck cancer. Several LLLT protocols are outlined by the guideline based on cancer treatment modality, ranging in wavelength from 632.9 to 660 nm.

### **American Physical Therapy Association**

In 2018, the American Physical Therapy Association published an updated guideline on the diagnosis and treatment of Achilles tendinitis.<sup>153</sup> The use of LLLT was given a level D recommendation, meaning that no recommendation could be made due to contradictory evidence. This is a change from the previous version of the guideline published in 2010, which gave LLLT a level B recommendation.<sup>154</sup>

### **National Institute for Health and Care Excellence**

In 2009, the National Institute for Health and Care Excellence issued guidance on early management of persistent, nonspecific low back pain and did not recommend laser treatment, citing limited evidence.<sup>155</sup> The 2016 and 2020 updated guidance does not mention laser therapy.<sup>155</sup>

### **North American Spine Society**

In 2020, the North American Spine Society published a guideline on the diagnosis and treatment of low back pain.<sup>156</sup> The guideline was based on a systematic review of the literature to address key clinical questions regarding the diagnosis and treatment of adults with nonspecific low back pain.

**Table 18. North American Spine Society Guideline Recommendations for Laser Therapy**

<b>Guideline Recommendation</b>	<b>Grade of Recommendation</b>
"It is suggested that the combination of laser therapy (low-level or high-level) with exercise provides better short-term relief of pain than either exercise or laser therapy alone."	B
"There is conflicting evidence that the combination of laser therapy with exercise provides better short-term improvement in function compared to exercise or laser therapy alone."	I
"It is suggested that there is no short-term benefit of laser therapy (low-level or high-level) when compared with exercise alone."	B

### **American College of Physicians**

In 2017, the American College of Physicians released guidelines relating to noninvasive treatments for chronic low back pain.<sup>157</sup> The guidelines strongly recommended that patients with chronic low back pain should first seek nonpharmacologic treatment such as exercise, multidisciplinary rehabilitation, acupuncture, and mindfulness-based stress reduction -- all based on moderate quality evidence. The recommendation also stated that patients with chronic low back pain should seek treatments such as tai chi, yoga, motor control exercise, progressive relaxation, electromyography biofeedback, LLLT, operant therapy, cognitive behavioral therapy, or spinal manipulation, all based on low-quality evidence. While the College stated that LLLT has a small effect on pain and function, it found the evidence insufficient for the use of LLLT.

In 2020, the American College of Physicians published a joint guideline on management of acute pain from non-low back musculoskeletal injuries with the American Academy of Family Physicians.<sup>158</sup> No recommendations are made specific to LLLT, but the guideline notes that laser therapy did not significantly reduce pain in 1 to 7 days compared to placebo.

### **American Academy of Orthopaedic Surgeons**

In 2016, the American Academy of Orthopaedic Surgeons' guidelines on management of carpal tunnel syndrome indicated the: "limited evidence supports that laser therapy might be effective compared to placebo."<sup>159</sup>

### **U.S. Preventive Services Task Force Recommendations**

Not applicable.

### **Ongoing and Unpublished Clinical Trials**

Some currently unpublished trials that might influence this review are listed in Table 19.

### **Table 19. Summary of Key Trials**

NCT: national clinical trial.

<sup>a</sup> Denotes industry-sponsored or cosponsored trial.

---

## **Government Regulations**

### **National:**

**National Coverage Determination (NCD) for LASER Procedures (140.5), Publication 100-3, effective date 5/1/1997**

### **Indications and Limitations of Coverage**

Medicare recognizes the use of lasers for many medical indications. Procedures performed with lasers are sometimes used in place of more conventional techniques. In the absence of a specific non-coverage instruction, and where a laser has been approved for marketing by the Food and Drug Administration, Medicare Administrative Contractor discretion may be used to determine whether a procedure performed with a laser is reasonable and necessary and therefore, covered.

The determination of coverage for a procedure performed using a laser is made on the basis that the use of lasers to alter, revise, or destroy tissue is a surgical procedure. Therefore,

coverage of laser procedures is restricted to practitioners with training in the surgical management of the disease or condition being treated.

### **Local:**

**Wisconsin Physicians Service Insurance Corporation**

**Local Coverage Article: Billing and Coding Category III Codes (A56902)**

**Original effective date: 08/29/2019**

**Revision Effective date: 10/01/2023**

Code 0552T is not listed as a reasonable and necessary code.

2024 WPS Medicare Physician Fee schedule does not list fees for 0552T S8948 and 97039. An assigned fee is not a guarantee of coverage.

*(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicare Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)*

---

### **Related Policies**

- Monochromatic Infrared Energy (MIRE) Device for the Treatment of Cutaneous Ulcers, Diabetic Neuropathy, and Miscellaneous Musculoskeletal Conditions
  - Temporomandibular Joint Dysfunction (TMJD) Testing and Treatment
- 

### **References**

1. Ezzati, E-Liisa, Amir et al. The Beneficial Effects of High-Intensity Laser Therapy and Co-Interventions on Musculoskeletal Pain Management: A Systematic Review. J Lasers Med Sci 2020 Winter, 11(1):81-90
2. Plaghki L, Mouraux A. EEG and laser stimulation as tools for pain research. Curr Opin Investig Drugs. 2005;6(1):58-64.
3. Aceituno-Gomez J, Avendano-Coy J, Gomez-Soriano J, et al. Efficacy of high-intensity laser therapy in subacromial impingement syndrome: A three-month follow-up controlled clinical trial. Clin Rehab. 2019. Jan 23:269215518824691.
4. Choi HW, Lee J, Lee S, Choi J, Lee K, Kim BK, Kim GJ. Effects of high intensity laser therapy on pain and function of patients with chronic back pain. J Phys Ther Sci. 2017 Jun;29(6):1079-1081.
5. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. May 15 2014;120(10):1453-1461. PMID 24615748
6. Schubert MM, Eduardo FP, Guthrie KA, et al. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer. Oct 2007;15(10):1145-1154. PMID 17393191

7. Figueiredo AL, Lins L, Cattony AC, et al. Laser therapy in the control of oral mucositis: A meta-analysis. *Rev Assoc Med Bras*. Oct 9 2013. PMID 24119379
8. Doeuk C, Hersant B, Bosc R, et al. Current indications for low level laser treatment in maxillofacial surgery: a review. *Br J Oral Maxillofac Surg*. Apr 2015;53(4):309-315. PMID 25740083
9. Peng J, Shi Y, Wang J, et al. Low-level laser therapy in the prevention and treatment of oral mucositis: a systematic review and meta-analysis. *Oral Surg Oral Med Oral Pathol Oral Radiol*. Oct 2020; 130(4): 387-397.e9. PMID32624448
10. Oberoi S, Zamperlini-Netto G, Beyene J, et al. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. *PLoS One*. 2014;9(9):e107418. PMID 25198431
11. Rankin IA, Sargeant H, Rehman H, et al. Low-level laser therapy for carpal tunnel syndrome. *Cochrane*.  
<https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012765/full>  
Published 22 August 2017. Accessed 9/6/22.
12. Li ZJ, Wang Y, Zhang HF, et al. Effectiveness of low-level laser on carpal tunnel syndrome: a meta-analysis of previously reported randomized trials. *Medicine (Baltimore)*. Aug 2016;95(31):e4424. PMID 27495063
13. Fusakul Y, Aranyavalai T, Saensri P, et al. Low-level laser therapy with a wrist splint to treat carpal tunnel syndrome: a double-blinded randomized controlled trial. *Lasers Med Sci*. May 2014;29(3):1279-1287. PMID 24477392
14. Low-level laser therapy for carpal tunnel syndrome and chronic neck pain. *Technol Eval Cent Assess Program Exec Summ*. Nov 2010; 25(4): 1-2. PMID 21638940
15. Chow RT, Heller GZ, Barnsley L. The effect of 300 mW, 830 nm laser on chronic neck pain: a double-blind, randomized, placebo-controlled study. *Pain*. Sep 2006; 124(1-2):201-10. PMID 16806710
16. Gross AR, Dziengo S, Boers O et al. Low Level Laser Therapy (LLLT) for Neck Pain: A Systematic Review and Meta-Regression. *Open Orthop J*. 2013; 7:396-419. PMID 24155802
17. Yeldan I, Cetin E, Ozdinciler AR. The effectiveness of low-level laser therapy on shoulder function in subacromial impingement syndrome. *Disabil Rehabil*. 2009;31(11):935-940. PMID 19031167
18. Dogan SK, Ay S, Evcik D. The effectiveness of low laser therapy in subacromial impingement syndrome: a randomized placebo controlled double-blind prospective study. *Clinics (Sao Paulo)*. 2010;65(10):1019-1022. PMID 21120304
19. Abrisham SM, Kermani-Alghoraishi M, Ghahramani R, et al. Additive effects of low-level laser therapy with exercise on subacromial syndrome: a randomised, double-blind, controlled trial. *Clin Rheumatol*. May 4 2011;30(10):1341-1346. PMID 21538218
20. Bal A, Eksioglu E, Gurcay E, et al. Low-level laser therapy in subacromial impingement syndrome. *Photomed Laser Surg*. Feb 2009;27(1):31-36. PMID 19250050
21. Calis HT, Berberoglu N, Calis M. Are ultrasound, laser and exercise superior to each other in the treatment of subacromial impingement syndrome? A randomized clinical trial. *Eur J Phys Rehabil Med*. Mar 2 2011;47(3):375-380. PMID 21364511
22. Alfredo PP, Bjordal JM, Junior WS, et al. Efficacy of low-level laser therapy combined with exercise for subacromial impingement syndrome: A randomised controlled trial. *Clin Rehabil*. Jun 2021; 35(6): 851-860. PMID 33307783

23. Güloğlu SB. Comparison of low-level laser treatment and extracorporeal shock wave therapy in subacromial impingement syndrome: a randomized, prospective clinical study. *Lasers Med Sci.* Jun 2021; 36(4): 773-781. PMID 32638239
24. Page MJ, Green S, Kramer S, et al. Electrotherapy modalities for adhesive capsulitis (frozen shoulder). *Cochrane Database Syst Rev.* Oct 1 2014;10:CD011324. PMID 25271097
25. Stergioulas A, et al. Effects of low-level laser therapy and eccentric exercises in the treatment of recreational athletes with chronic achilles tendinopathy. *Am J Sports Med.* May 2008; 36(5): 881-7. PMID 18272794
26. Chen J, Huang Z, Ge M, et al. Efficacy of low-level laser therapy in the treatment of TMDs: a meta-analysis of 14 randomised controlled trials. *J Oral Rehabil.* Apr 2015;42(4):291-299. PMID 25491183
27. Chang WD, Lee CL, Lin HY, et al. A meta-analysis of clinical effects of low-level laser therapy on temporomandibular joint pain. *J Phys Ther Sci.* Aug 2014;26(8):1297-1300. PMID 25202201
28. Hanna R, Dalvi S, Bensadoun RJ, et al. Role of Photobiomodulation Therapy in Modulating Oxidative Stress in Temporomandibular Disorders. A Systematic Review and Meta-Analysis of Human Randomised Controlled Trials. *Antioxidants (Basel).* Jun 25 2021; 10(7). PMID 34202292
29. Conti PC. Low level laser therapy in the treatment of temporomandibular disorders (TMD): a double-blind pilot study. *Cranio.* Apr 1997; 15(2): 144-9. PMID 9586517
30. Kulekcioglu S, Sivrioglu K, Ozcan O, et al. Effectiveness of low-level laser therapy in temporomandibular disorder. *Scand J Rheumatol.* 2003; 32(2): 114-8. PMID 12737331
31. Venancio Rde A, Camparis CM, Lizarelli Rde F. Low intensity laser therapy in the treatment of temporomandibular disorders: a double-blind study. *J Oral Rehabil.* Nov 2005; 32(11): 800-7. PMID 16202043
32. Cetiner S, Kahraman SA, Yucetas S. Evaluation of low-level laser therapy in the treatment of temporomandibular disorders. *Photomed Laser Surg.* Oct 2006; 24(5): 637-41. PMID 17069496
33. Fikackova H, Dostalova T, Navratil L, et al. Effectiveness of low-level laser therapy in temporomandibular joint disorders: a placebo-controlled study. *Photomed Laser Surg.* Aug 2007; 25(4): 297-303. PMID 17803388
34. Mazzetto MO, Carrasco TG, Bidinelo EF, et al. Low intensity laser application in temporomandibular disorders: a phase I double-blind study. *Cranio.* Jul 2007; 25(3): 186-92. PMID 17696035
35. Frare J.C., Nicolau R.A. Clinical analysis of the effect of laser photobiomodulation (GaAs904 nm) on temporomandibular joint dysfunction. *Rev. Bras. Fisioter.* 2008;12:3742. doi: 10.1590/S1413-35552008000100008.
36. da Cunha LA, Firoozmand LM, da Silva AP, et al. Efficacy of low-level laser therapy in the treatment of temporomandibular disorder. *Int Dent J.* Aug 2008; 58(4): 213-7. PMID 18783114
37. Lassemi E., Jafari S.M., Motamedi M.H.K., Navi F., Lasemi R. Low- level laser therapy in the management of temporamandibular joint disorder. *J. Oral Laser Appl.* 2008;8:8386
38. Carrasco TG, Mazzetto MO, Mazzetto RG, et al. Low intensity laser therapy in temporomandibular disorder: a phase II double-blind study. *Cranio.* Oct 2008; 26(4): 274-81. PMID 19004308

39. Emshoff R, Bosch R, Pumpel E, et al. Low-level laser therapy for treatment of temporomandibular joint pain: a double-blind and placebo-controlled trial. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* Apr 2008; 105(4): 452-6. PMID 18329580
40. Carrasco TG, Guerisoli LD, Guerisoli DM, et al. Evaluation of low intensity laser therapy in myofascial pain syndrome. *Cranio.* Oct 2009; 27(4): 243-7. PMID 19891258
41. Shirani AM, Gutknecht N, Taghizadeh M, et al. Low-level laser therapy and myofascial pain dysfunction syndrome: a randomized controlled clinical trial. *Lasers Med Sci.* Sep 2009; 24(5): 715-20. PMID 19002646
42. Venezian GC, da Silva MA, Mazzetto RG, et al. Low level laser effects on pain to palpation and electromyographic activity in TMD patients: a double-blind, randomized, placebo-controlled study. *Cranio.* Apr 2010; 28(2): 84-91. PMID 20491229
43. Oz S, Gokcen-Rohlig B, Saruhanoglu A, et al. Management of myofascial pain: low-level laser therapy versus occlusal splints. *J Craniofac Surg.* Nov 2010; 21(6): 1722-8. PMID 21119408
44. Marini I, Gatto MR, Bonetti GA. Effects of superpulsed low-level laser therapy on temporomandibular joint pain. *Clin J Pain.* Sep 2010; 26(7): 611-6. PMID 20664343
45. Rohlig B.G., Kipirdi S., Meric U., Capan N., Keskin H. Masticatory muscle pain and low-level laser therapy: A double-blind and placebo-controlled study. *Turk. J. Phys. Med. Rehabil. Turk. Fiz. Tip Rehabil. Derg.* 2011;57:3137. doi: 10.4274/tftr.57.06.
46. Sattayut S, Bradley P. A study of the influence of low intensity laser therapy on painful temporomandibular disorder patients. *Laser Ther.* Sep 30 2012; 21(3): 183-92. PMID 24511188
47. de Carli ML, Guerra MB, Nunes TB, et al. Piroxicam and laser phototherapy in the treatment of TMJ arthralgia: a double-blind randomised controlled trial. *J Oral Rehabil.* Mar 2013; 40(3): 171-8. PMID 23252583
48. da Silva MA, Botelho AL, Turim CV, et al. Low level laser therapy as an adjunctive technique in the management of temporomandibular disorders. *Cranio.* Oct 2012; 30(4): 264-71. PMID 23156967
49. Panhoca VH, Lizarelli Rde F, Nunez SC, et al. Comparative clinical study of light analgesic effect on temporomandibular disorder (TMD) using red and infrared led therapy. *Lasers Med Sci.* Feb 2015; 30(2): 815-22. PMID 24197518
50. Uemoto L, Garcia MA, Gouvea CV, et al. Laser therapy and needling in myofascial trigger point deactivation. *J Oral Sci.* 2013; 55(2): 175-81. PMID 23748458
51. Ferreira LA, de Oliveira RG, Guimaraes JP, et al. Laser acupuncture in patients with temporomandibular dysfunction: a randomized controlled trial. *Lasers Med Sci.* Nov 2013; 28(6): 1549-58. PMID 23380907
52. Demirkol N, Sari F, Bulbul M, et al. Effectiveness of occlusal splints and low-level laser therapy on myofascial pain. *Lasers Med Sci.* Apr 2015; 30(3): 1007-12. PMID 24504660
53. Ahrari F, Madani AS, Ghafouri ZS, et al. The efficacy of low-level laser therapy for the treatment of myogenous temporomandibular joint disorder. *Lasers Med Sci.* Mar 2014; 29(2): 551-7. PMID 23318917
54. Pereira TS, Flecha OD, Guimaraes RC, et al. Efficacy of red and infrared lasers in treatment of temporomandibular disorders--a double-blind, randomized, parallel clinical trial. *Cranio.* Jan 2014; 32(1): 51-6. PMID 24660647
55. de Moraes Maia ML, Ribeiro MA, Maia LG, et al. Evaluation of low-level laser therapy effectiveness on the pain and masticatory performance of patients with myofascial pain. *Lasers Med Sci.* Jan 2014; 29(1): 29-35. PMID 23143142

56. Sancakli E, Gokcen-Rohlig B, Balik A, et al. Early results of low-level laser application for masticatory muscle pain: a double-blind randomized clinical study. *BMC Oral Health*. Oct 23 2015; 15(1): 131. PMID 26496720
57. Douglas De Oliveira DW, Lages FS, Guimaraes RC, et al. Do TMJ symptoms improve and last across time after treatment with red (660 nm) and infrared (790 nm) low level laser treatment (LLLT)? A survival analysis. *Cranio*. Nov 2017; 35(6): 372-378. PMID 28218006
58. Costa SAP, Florezi GP, Artes GE, et al. The analgesic effect of photobiomodulation therapy (830 nm) on the masticatory muscles: a randomized, double-blind study. *Braz Oral Res*. Dec 18 2017; 31: e107. PMID 29267668
59. Seifi M, Ebadifar A, Kabiri S, et al. Comparative effectiveness of Low Level Laser therapy and Transcutaneous Electric Nerve Stimulation on Temporomandibular Joint Disorders. *J Lasers Med Sci*. 2017; 8(Suppl 1): S27-S31. PMID 29071032
60. Shobha R, Narayanan VS, Jagadish Pai BS, et al. Low-level laser therapy: A novel therapeutic approach to temporomandibular disorder - A randomized, double-blinded, placebo-controlled trial. *Indian J Dent Res*. Jul-Aug 2017; 28(4): 380-387. PMID 28836528
61. Rezazadeh F, Hajian K, Shahidi S, et al. Comparison of the Effects of Transcutaneous Electrical Nerve Stimulation and Low-Level Laser Therapy on Drug-Resistant Temporomandibular Disorders. *J Dent (Shiraz)*. Sep 2017; 18(3): 187-192. PMID 29034273
62. Varma S, al Shayeb M, el Shayeb E, et al. Effectiveness of low-level laser therapy in the Management of the Temporomandibular Joint Disorders: A Placebo-controlled Trial. *World J. Dent*. 2018;9:316320. doi: 10.5005/jp-journals-10015-1555.
63. Borges RMM, Cardoso DS, Flores BC, et al. Effects of different photobiomodulation dosimetries on temporomandibular dysfunction: a randomized, double-blind, placebo-controlled clinical trial. *Lasers Med Sci*. Dec 2018; 33(9): 1859-1866. PMID 29850961
64. Brochado FT, Jesus LH, Carrard VC, et al. Comparative effectiveness of photobiomodulation and manual therapy alone or combined in TMD patients: a randomized clinical trial. *Braz Oral Res*. Jul 10 2018; 32: e50. PMID 29995062
65. Rodrigues CA, Melchior MO, Valencise Magri L, et al. Can the severity of orofacial myofunctional conditions interfere with the response of analgesia promoted by active or placebo low-level laser therapy?. *Cranio*. Jul 2020; 38(4): 240-247. PMID 30244669
66. Peimani A, Keshavarz S, Fathollahi MS. Comparison of Low-Level Laser Therapy and Drug Therapy in Patients with Temporomandibular Disorders: A Randomized Clinical Trial. *J. Oral Health Dent*. 2020;38:240247. doi: 10.1080/08869634.2018.1520950.
67. Nadershah M, Abdel-Alim HM, Bayoumi AM, et al. Photobiomodulation Therapy for Myofascial Pain in Temporomandibular Joint Dysfunction: A Double-Blinded Randomized Clinical Trial. *J Maxillofac Oral Surg*. Mar 2020; 19(1): 93-97. PMID 31988570
68. Magri LV, Bataglion C, Leite-Panissi CRA. Follow-up results of a randomized clinical trial for low-level laser therapy in painful TMD of muscular origins. *Cranio*. Nov 2021; 39(6): 502-509. PMID 31585522
69. Al-Quisi AF, Al-Anee AM, Al-Jumaily HA, et al. Efficacy of the LED Red Light Therapy in the Treatment of Temporomandibular Disorders: Double Blind Randomized Controlled Trial. *Pain Res Treat*. 2019; 2019: 8578703. PMID 31205787
70. Herpich CM, Leal-Junior ECP, Politti F, et al. Intraoral photobiomodulation diminishes pain and improves functioning in women with temporomandibular disorder: a

randomized, sham-controlled, double-blind clinical trial : Intraoral photobiomodulation diminishes pain in women with temporomandibular disorder. *Lasers Med Sci.* Mar 2020; 35(2): 439-445. PMID 31325122

71. Khairnar S, Bhate K, S N SK, et al. Comparative evaluation of low-level laser therapy and ultrasound heat therapy in reducing temporomandibular joint disorder pain. *J Dent Anesth Pain Med.* Oct 2019; 19(5): 289-294. PMID 31723669
72. Sobral APT, Godoy CLH, Fernandes KPS, et al. Photomodulation in the treatment of chronic pain in patients with temporomandibular disorder: protocol for cost-effectiveness analysis. *BMJ Open.* May 05 2018; 8(5): e018326. PMID 29730613
73. Maracci LM, Stasiak G, de Oliveira Chami V, et al. Treatment of myofascial pain with a rapid laser therapy protocol compared to occlusal splint: A double-blind, randomized clinical trial. *Cranio.* Jun 03 2020: 1-7. PMID 32491964
74. Chellappa D, Thirupathy M. Comparative efficacy of low-Level laser and TENS in the symptomatic relief of temporomandibular joint disorders: A randomized clinical trial. *Indian J Dent Res.* Jan-Feb 2020; 31(1): 42-47. PMID 32246680
75. Monteiro L, Ferreira R, Resende T, et al. Effectiveness of Photobiomodulation in Temporomandibular Disorder-Related Pain Using a 635 nm Diode Laser: A Randomized, Blinded, and Placebo-Controlled Clinical Trial. *Photobiomodul Photomed Laser Surg.* May 2020; 38(5): 280-288. PMID 32427553
76. Del Vecchio A, Floravanti M, Boccassini A, et al. Evaluation of the efficacy of a new low-level laser therapy home protocol in the treatment of temporomandibular joint disorder-related pain: A randomized, double-blind, placebo-controlled clinical trial. *Cranio.* Mar 2021; 39(2): 141-150. PMID 30999823
77. Aisaiti A, Zhou Y, Wen Y, et al. Effect of photobiomodulation therapy on painful temporomandibular disorders. *Sci Rep.* Apr 27 2021; 11(1): 9049. PMID 33907210
78. Glazov G, Yelland M, Emery J. Low-level laser therapy for chronic non-specific low back pain: a meta-analysis of randomised controlled trials. *Acupunct Med.* Oct 2016; 34(5): 328-341. PMID 27207675
79. Huang Z, Ma J, Chen J, et al. The effectiveness of low-level laser therapy for nonspecific chronic low back pain: a systematic review and meta-analysis. *Arthritis Res Ther.* Dec 15 2015; 17: 360. PMID 26667480
80. Chen YJ, Liao CD, Hong JP, et al. Effects of laser therapy on chronic low back pain: A systematic review and meta-analysis of randomized controlled trials. *Clin Rehabil.* Mar 2022; 36(3): 289-302. PMID 34757882
81. Alayat MS, Atya AM, Ali MM, et al. Long-term effect of high-intensity laser therapy in the treatment of patients with chronic low back pain: a randomized blinded placebo-controlled trial. *Lasers Med Sci.* May 2014; 29(3): 1065-73. PMID 24178907
82. Ay S, Dogan SK, Evcik D. Is low-level laser therapy effective in acute or chronic low back pain?. *Clin Rheumatol.* Aug 2010; 29(8): 905-10. PMID 20414695
83. Basford JR, Sheffield CG, Harmsen WS. Laser therapy: a randomized, controlled trial of the effects of low-intensity Nd:YAG laser irradiation on musculoskeletal back pain. *Arch Phys Med Rehabil.* Jun 1999; 80(6): 647-52. PMID 10378490
84. Djavid GE, Mehrdad R, Ghasemi M, et al. In chronic low back pain, low level laser therapy combined with exercise is more beneficial than exercise alone in the long term: a randomised trial. *Aust J Physiother.* 2007; 53(3): 155-60. PMID 17725472
85. Glazov G, Schattner P, Lopez D, et al. Laser acupuncture for chronic non-specific low back pain: a controlled clinical trial. *Acupunct Med.* Sep 2009; 27(3): 94-100. PMID 19734378

86. Glazov G, Yelland M, Emery J. Low-dose laser acupuncture for non-specific chronic low back pain: a double-blind randomised controlled trial. *Acupunct Med.* Apr 2014; 32(2): 116-23. PMID 24280948
87. Klein RG, Eek BC. Low-energy laser treatment and exercise for chronic low back pain: double-blind controlled trial. *Arch Phys Med Rehabil.* Jan 1990; 71(1): 34-7. PMID 2136991
88. Konstantinovic L, Lazovic M, Milovanovic N, et al.. Low level laser therapy in geriatric patients with low back pain. *Eur J Pain Suppl (Poster Sessions)* 2011;5:61 10.1016/S1754-3207(11)70205-X
89. Lin ML, Wu HC, Hsieh YH, et al. Evaluation of the effect of laser acupuncture and cupping with ryodoraku and visual analog scale on low back pain. *Evid Based Complement Alternat Med.* 2012; 2012: 521612. PMID 23118792
90. Okamoto H. Therapeutic effect of semiconductor laser irradiation on low-back pain. *J Jpn A Phys Med Balneology Climatology* 1989;52:13145.
91. Ruth M, Weber M, Zenz M. [Laser acupuncture for chronic back pain. A double-blind clinical study]. *Schmerz.* Sep 2010; 24(5): 485-93. PMID 20872127
92. Soriano F, Rios R. Gallium arsenide laser treatment of chronic low back pain: a prospective, randomized and double blind study. *Laser Ther* 1998;10:17580. 10.5978/islsm.10.175
93. Umegaki S. Effectiveness of low-power laser therapy on low-back pain: double blind comparative study to evaluate the analgesic effect of low-power laser therapy. *Kiso to Rinsho (The Clinical Report)* 1989;23:283946.
94. Vallone F, Benedicenti S, Sorrenti E, et al. Effect of diode laser in the treatment of patients with nonspecific chronic low back pain: a randomized controlled trial. *Photomed Laser Surg.* Sep 2014; 32(9): 490-4. PMID 25141218
95. Wallace G. The effects of laser acupuncture on chronic low back pain [Thesis]. Melbourne Monash University, 1996.
96. Gur A, Karakoc M, Cevik R, et al. Efficacy of low power laser therapy and exercise on pain and functions in chronic low back pain. *Lasers Surg Med.* 2003; 32(3): 233-8. PMID 12605431
97. Hsieh RL, Lee WC. Short-term therapeutic effects of 890-nanometer light therapy for chronic low back pain: a double-blind randomized placebo-controlled study. *Lasers Med Sci.* Mar 2014; 29(2): 671-9. PMID 23820974
98. de Carvalho ME, de Carvalho RM, Marques AP, et al. Low intensity laser and LED therapies associated with lateral decubitus position and flexion exercises of the lower limbs in patients with lumbar disk herniation: clinical randomized trial. *Lasers Med Sci.* Sep 2016; 31(7): 1455-63. PMID 27379776
99. Tantawy SA, Abdelbasset WK, Kamel DM, et al. Laser photobiomodulation is more effective than ultrasound therapy in patients with chronic nonspecific low back pain: a comparative study. *Lasers Med Sci.* Jun 2019; 34(4): 793-800. PMID 30334124
100. Nambi G, Kamal W, Es S, et al. Spinal manipulation plus laser therapy versus laser therapy alone in the treatment of chronic non-specific low back pain: a randomized controlled study. *Eur J Phys Rehabil Med.* Dec 2018; 54(6): 880-889. PMID 29687966
101. Shin JY, Ku B, Kim JU, et al. Short-Term Effect of Laser Acupuncture on Lower Back Pain: A Randomized, Placebo-Controlled, Double-Blind Trial. *Evid Based Complement Alternat Med.* 2015; 2015: 808425. PMID 26516333

102. Koldas Dogan S, Ay S, Evcik D. The effects of two different low level laser therapies in the treatment of patients with chronic low back pain: A double-blinded randomized clinical trial. *J Back Musculoskelet Rehabil.* 2017; 30(2): 235-240. PMID 27472858
103. Huang Z, Chen J, Ma J, et al. Effectiveness of low-level laser therapy in patients with knee osteoarthritis: a systematic review and meta-analysis. *Osteoarthritis Cartilage.* Sep 2015; 23(9): 1437-1444. PMID 25914044
104. Bjordal JM, Johnson MI, Lopes-Martins RA, et al. Short-term efficacy of physical interventions in osteoarthritic knee pain. A systematic review and meta-analysis of randomised placebo-controlled trials. *BMC Musculoskelet Disord.* Jun 22 2007; 8: 51. PMID 17587446
105. Stausholm MB, Naterstad IF, Joensen J, et al. Efficacy of low-level laser therapy on pain and disability in knee osteoarthritis: systematic review and meta-analysis of randomised placebo-controlled trials. *BMJ Open.* Oct 28 2019; 9(10): e031142. PMID 31662383
106. Al Rashoud AS, Abboud RJ, Wang W, et al. Efficacy of low-level laser therapy applied at acupuncture points in knee osteoarthritis: a randomised double-blind comparative trial. *Physiotherapy.* Sep 2014; 100(3): 242-8. PMID 24418801
107. Alfredo PP, Bjordal JM, Dreyer SH, et al. Efficacy of low level laser therapy associated with exercises in knee osteoarthritis: a randomized double-blind study. *Clin Rehabil.* Jun 2012; 26(6): 523-33. PMID 22169831
108. Alfredo PP, Bjordal JM, Junior WS, et al. Long-term results of a randomized, controlled, double-blind study of low-level laser therapy before exercises in knee osteoarthritis: laser and exercises in knee osteoarthritis. *Clin Rehabil.* Feb 2018; 32(2): 173-178. PMID 28776408
109. Alghadir A, Omar MT, Al-Askar AB, et al. Effect of low-level laser therapy in patients with chronic knee osteoarthritis: a single-blinded randomized clinical study. *Lasers Med Sci.* Mar 2014; 29(2): 749-55. PMID 23912778
110. Bagheri SR, Fatemi E, Fazeli SH, et al. Efficacy of low level laser on knee osteoarthritis treatment [Persian]. *Koomesh* 2011;12:28592.
111. Bulow PM, Jensen H, Danneskiold-Samsøe B. Low power Ga-Al-As laser treatment of painful osteoarthritis of the knee. A double-blind placebo-controlled study. *Scand J Rehabil Med.* Sep 1994; 26(3): 155-9. PMID 7801065
112. Delkhosh CT, Fatemy E, Ghorbani R, et al. Comparing the immediate and long-term effects of low and high power laser on the symptoms of knee osteoarthritis [Persian]. *Journal of mazandaran university of medical sciences* 2018;28:6977.
113. Fukuda VO, Fukuda TY, Guimaraes M, et al. SHORT-TERM EFFICACY OF LOW-LEVEL LASER THERAPY IN PATIENTS WITH KNEE OSTEOARTHRITIS: A RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL. *Rev Bras Ortop.* Sep-Oct 2011; 46(5): 526-33. PMID 27027049
114. Gur A, Cosut A, Sarac AJ, et al. Efficacy of different therapy regimes of low-power laser in painful osteoarthritis of the knee: a double-blind and randomized-controlled trial. *Lasers Surg Med.* 2003; 33(5): 330-8. PMID 14677160
115. Gworys K, Gasztych J, Puzder A, et al. Influence of various laser therapy methods on knee joint pain and function in patients with knee osteoarthritis. *Ortop Traumatol Rehabil.* May-Jun 2012; 14(3): 269-77. PMID 22764339
116. Hegedus B, Viharos L, Gervain M, et al. The effect of low-level laser in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial. *Photomed Laser Surg.* Aug 2009; 27(4): 577-84. PMID 19530911

117. Helianthi DR, Simadibrata C, Srilestari A, et al. Pain Reduction After Laser Acupuncture Treatment in Geriatric Patients with Knee Osteoarthritis: a Randomized Controlled Trial. *Acta Med Indones*. Apr 2016; 48(2): 114-21. PMID 27550880
118. Hinman RS, McCrory P, Pirotta M, et al. Acupuncture for chronic knee pain: a randomized clinical trial. *JAMA*. Oct 01 2014; 312(13): 1313-22. PMID 25268438
119. Jensen H, Harreby M, Kjer J. [Infrared laser--effect in painful arthrosis of the knee?]. *Ugeskr Laeger*. Nov 09 1987; 149(46): 3104-6. PMID 3445368
120. Kheshie AR, Alayat MS, Ali MM. High-intensity versus low-level laser therapy in the treatment of patients with knee osteoarthritis: a randomized controlled trial. *Lasers Med Sci*. Jul 2014; 29(4): 1371-6. PMID 24487957
121. Koutenaei FR, Mosallanezhad Z, Naghikhani M, et al.. The effect of low level laser therapy on pain and range of motion of patients with knee osteoarthritis. *Physical Treatments - Specific Physical Therapy* 2017;7:1318.
122. Mohammed N, Allam H, Elghoroury E, et al. Evaluation of serum beta-endorphin and substance P in knee osteoarthritis patients treated by laser acupuncture. *J Complement Integr Med*. Jan 05 2018; 15(2). PMID 29303777
123. S GN, Kamal W, George J, et al. Radiological and biochemical effects (CTX-II, MMP-3, 8, and 13) of low-level laser therapy (LLLT) in chronic osteoarthritis in Al-Kharj, Saudi Arabia. *Lasers Med Sci*. Feb 2017; 32(2): 297-303. PMID 27913970
124. Nivbrant B, Friberg S. [Laser treatment of knee joint arthrosis seems to be effective but scientific evidence is lacking]. *Lakartidningen*. Mar 11 1992; 89(11): 859-61. PMID 1545640
125. Rayegani SM, Bahrami MH, Elyaspour D, et al.. Therapeutic effects of low level laser therapy (LLLT) in knee osteoarthritis, compared to therapeutic ultrasound. *J Lasers Med Sci* 2012;3:7174.
126. Tascioglu F, Armagan O, Tabak Y, et al. Low power laser treatment in patients with knee osteoarthritis. *Swiss Med Wkly*. May 01 2004; 134(17-18): 254-8. PMID 15243853
127. Youssef EF, Muaidi QI, Shanb AA. Effect of Laser Therapy on Chronic Osteoarthritis of the Knee in Older Subjects. *J Lasers Med Sci*. 2016; 7(2): 112-9. PMID 27330707
128. Tumilty S, McDonough S, Hurley DA, et al. Clinical effectiveness of low-level laser therapy as an adjunct to eccentric exercise for the treatment of Achilles' tendinopathy: a randomized controlled trial. *Arch Phys Med Rehabil*. May 2012; 93(5): 733-9. PMID 22541305
129. Wang W, Jiang W, Tang C, et al. Clinical efficacy of low-level laser therapy in plantar fasciitis: A systematic review and meta-analysis. *Medicine (Baltimore)*. Jan 2019; 98(3): e14088. PMID 30653125
130. Guimaraes JS, Arcanjo FL, Leporace G, et al. Effect of low-level laser therapy on pain and disability in patients with plantar fasciitis: A systematic review and meta-analysis. *Musculoskelet Sci Pract*. Feb 2022; 57: 102478. PMID 34847470
131. Macias DM, Coughlin MJ, Zang K, et al. Low-Level Laser Therapy at 635 nm for Treatment of Chronic Plantar Fasciitis: A Placebo-Controlled, Randomized Study. *J Foot Ankle Surg*. Sep-Oct 2015; 54(5): 768-72. PMID 25769363
132. Kiritsi O, Tsitas K, Malliaropoulos N, et al. Ultrasonographic evaluation of plantar fasciitis after low-level laser therapy: results of a double-blind, randomized, placebo-controlled trial. *Lasers Med Sci*. Mar 2010; 25(2): 275-81. PMID 19841862

133. Cinar E, Saxena S, Uygur F. Low-level laser therapy in the management of plantar fasciitis: a randomized controlled trial. *Lasers Med Sci.* Jul 2018; 33(5): 949-958. PMID 29273892
134. Brosseau L, Robinson V, Wells G, et al. Low level laser therapy (Classes I, II and III) for treating rheumatoid arthritis. *Cochrane Database Syst Rev.* Oct 19 2005; (4): CD002049. PMID 16235295
135. Meireles SM, Jones A, Jennings F, et al. Assessment of the effectiveness of low-level laser therapy on the hands of patients with rheumatoid arthritis: a randomized double-blind controlled trial. *Clin Rheumatol.* May 2010; 29(5): 501-9. PMID 20082104
136. Alayat MS, Elsodany AM, El Fiky AA. Efficacy of high and low level laser therapy in the treatment of Bell's palsy: a randomized double blind placebo-controlled trial. *Lasers Med Sci.* Jan 2014; 29(1): 335-42. PMID 23709010
137. Ordahan B, Karahan AY. Role of low-level laser therapy added to facial expression exercises in patients with idiopathic facial (Bell's) palsy. *Lasers Med Sci.* May 2017; 32(4): 931-936. PMID 28337563
138. Honda Y, Sakamoto J, Hamaue Y, et al. Effects of Physical-Agent Pain Relief Modalities for Fibromyalgia Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Pain Res Manag.* 2018; 2018: 2930632. PMID 30402199
139. Ruaro JA, Frez AR, Ruaro MB, et al. Low-level laser therapy to treat fibromyalgia. *Lasers Med Sci.* Nov 2014; 29(6): 1815-9. PMID 24801056
140. Matsutani LA, Marques AP, Ferreira EA, et al. Effectiveness of muscle stretching exercises with and without laser therapy at tender points for patients with fibromyalgia. *Clin Exp Rheumatol.* May-Jun 2007; 25(3): 410-5. PMID 17631737
141. Samson D, Lefevre F, Aronson N. Wound-healing technologies: low-level laser and vacuum-assisted closure. *Evid Rep Technol Assess (Summ).* Dec 2004; (111): 1-6. PMID 15663354
142. Chen C, Hou WH, Chan ES, et al. Phototherapy for treating pressure ulcers. *Cochrane Database Syst Rev.* Jul 11 2014; (7): CD009224. PMID 25019295
143. Machado RS, Viana S, Sbruzzi G. Low-level laser therapy in the treatment of pressure ulcers: systematic review. *Lasers Med Sci.* May 2017; 32(4): 937-944. PMID 28116536
144. Taradaj J, Halski T, Kucharzewski M, et al. Effect of laser irradiation at different wavelengths (940, 808, and 658 nm) on pressure ulcer healing: results from a clinical study. *Evid Based Complement Alternat Med* 2013;2013:960240. PMID
145. Lucas C, van Gemert MJ, de Haan RJ. Efficacy of low-level laser therapy in the management of stage III decubitus ulcers: a prospective, observer-blinded multicentre randomised clinical trial. *Lasers Med Sci.* 2003; 18(2): 72-7. PMID 12928815
146. Nussbaum EL, Biemann I, Mustard B. Comparison of ultrasound/ultraviolet-C and laser for treatment of pressure ulcers in patients with spinal cord injury. *Phys Ther.* Sep 1994; 74(9): 812-23; discussion 824-5. PMID 8066108
147. Taly AB, Sivaraman Nair KP, Murali T, et al. Efficacy of multiwavelength light therapy in the treatment of pressure ulcers in subjects with disorders of the spinal cord: A randomized double-blind controlled trial. *Arch Phys Med Rehabil.* Oct 2004; 85(10): 1657-61. PMID 15468027
148. Li S, Wang C, Wang B, et al. Efficacy of low-level light therapy for treatment of diabetic foot ulcer: A systematic review and meta-analysis of randomized controlled trials. *Diabetes Res Clin Pract.* Sep 2018; 143: 215-224. PMID 30009935

149. Smoot B, Chiavola-Larson L, Lee J, et al. Effect of low-level laser therapy on pain and swelling in women with breast cancer-related lymphedema: a systematic review and meta-analysis. *J Cancer Surviv.* Jun 2015; 9(2): 287-304. PMID 25432632
150. Omar MT, Shaheen AA, Zafar H. A systematic review of the effect of low-level laser therapy in the management of breast cancer-related lymphedema. *Support Care Cancer.* Nov 2012; 20(11): 2977-84. PMID 22875413
151. Sung L, Robinson P, Treister N, et al. Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation. *BMJ Support Palliat Care.* Mar 2017; 7(1): 7-16. PMID 25818385
152. Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. *Cancer.* Oct 01 2020; 126(19): 4423-4431. PMID 32786044
153. Martin RL, Chimenti R, Cuddeford T, et al. Achilles Pain, Stiffness, and Muscle Power Deficits: Midportion Achilles Tendinopathy Revision 2018. *J Orthop Sports Phys Ther.* May 2018; 48(5): A1-A38. PMID 29712543
154. Carcia CR, Martin RL, Houck J, et al. Achilles pain, stiffness, and muscle power deficits: achilles tendinitis. *J Orthop Sports Phys Ther.* Sep 2010; 40(9): A1-26. PMID 20805627
155. National Institute for Health and Care Excellence (NICE). Low back pain in adults: early management [CG88]. 2009; [Overview | Low back pain and sciatica in over 16s: assessment and management | Guidance | NICE](#) Accessed 2/8/2024.
156. North American Spine Society. Evidence-based clinical guidelines for multidisciplinary spine care. 2020.  
<https://www.spine.org/Portals/0/assets/downloads/ResearchClinicalCare/Guidelines/LowBackPain.pdf> Accessed 2/8/2024
157. Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. *Ann Intern Med.* Apr 04 2017; 166(7): 514-530. PMID 28192789
158. Qaseem A, McLean RM, O'Gurek D, et al. Nonpharmacologic and Pharmacologic Management of Acute Pain From Non-Low Back, Musculoskeletal Injuries in Adults: A Clinical Guideline From the American College of Physicians and American Academy of Family Physicians. *Ann Intern Med.* Nov 03 2020; 173(9): 739-748. PMID 32805126
159. American Academy of Orthopaedic Surgeons. Management of Carpal Tunnel Syndrome: Evidence-Based Clinical Guideline. 2016;  
<https://www.aaos.org/quality/quality-programs/upper-extremity-programs/carpal-tunnel-syndrome/> Accessed 2/8/2024.

*The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through 2/8/2024, the date the research was completed.*

### Joint BCBSM/BCN Medical Policy History

<b>Policy Effective Date</b>	<b>BCBSM Signature Date</b>	<b>BCN Signature Date</b>	<b>Comments</b>
9/22/03	9/22/03	10/3/03	Joint policy established
1/1/07	10/31/06	11/6/06	Routine maintenance
1/1/09	10/13/08	12/30/08	Routine maintenance
9/1/11	6/21/11	6/21/11	Routine maintenance; policy title changed from “Low-Level Laser Therapy for the Treatment of Carpal Tunnel Syndrome” to “Low Level Laser Therapy”.
11/1/12	8/21/12	8/21/12	Routine maintenance
3/1/15	12/12/14	12/29/14	Routine maintenance
7/1/16	4/19/16	5/23/16	Routine maintenance Policy position changed to established for prevention of oral mucositis in patients undergoing treatment. All other indications remain experimental/investigational.
7/1/17	4/18/17	4/18/17	Routine maintenance
7/1/18	4/17/18	4/17/18	Routine maintenance
7/1/19	4/16/19		Routine maintenance
7/1/20	4/14/20		Routine maintenance
7/1/21	4/20/21		Routine maintenance Code 0552T added
11/1/21	8/17/21		Clarification: code S8948 will be moved to investigational code section.
7/1/22	4/19/22		Routine maintenance Ref added 18,40,113
1/1/23	10/18/22		Routine maintenance (ls) Ref added 19,24,73,76,126
7/1/23	4/26/23		Routine maintenance (jf) Added references 1, 2, 3. Added high power laser therapy in title, description, medical policy statement. FDA information added.

			Vendor Managed: NA Add LLLT under Inclusion section. <ul style="list-style-type: none"> <li>Under Exclusions add separated HPLT bullet: High Power Laser Therapy for all indications</li> <li>Added summary section for HPLT</li> </ul>
3/1/24	12/19/23		2024 CPT Update: Add 97037 as E/I effective 1/1/24 (jf) Vendor managed: NA
7/1/24	4/16/24		Routine maintenance (jf) Vendor Managed: NA No change in policy status

Next Review Date: 2nd Qtr, 2025

**BLUE CARE NETWORK BENEFIT COVERAGE**  
**POLICY: LOW-LEVEL LASER THERAPY AND HIGH-POWER LASER THERAPY**

**I. Coverage Determination:**

<b>Commercial HMO (includes Self-Funded groups unless otherwise specified)</b>	Covered; policy criteria applies
<b>BCNA (Medicare Advantage)</b>	See Government Regulations section.
<b>BCN65 (Medicare Complementary)</b>	Coinsurance covered if primary Medicare covers the service.

**II. Administrative Guidelines:**

- The member's contract must be active at the time the service is rendered.
- Coverage is based on each member's certificate and is not guaranteed. Please consult the individual member's certificate for details. Additional information regarding coverage or benefits may also be obtained through customer or provider inquiry services at BCN.
- The service must be authorized by the member's PCP except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Services must be performed by a BCN-contracted provider, if available, except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Payment is based on BCN payment rules, individual certificate and certificate riders.
- Appropriate copayments will apply. Refer to certificate and applicable riders for detailed information.
- CPT - HCPCS codes are used for descriptive purposes only and are not a guarantee of coverage.